<SEC-DOCUMENT>0000914121-21-000581.txt : 20210203
<SEC-HEADER>0000914121-21-000581.hdr.sgml : 20210203
<ACCEPTANCE-DATETIME>20210203162741
ACCESSION NUMBER:		0000914121-21-000581
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210129
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210203
DATE AS OF CHANGE:		20210203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANGIODYNAMICS INC
		CENTRAL INDEX KEY:			0001275187
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				113146460
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50761
		FILM NUMBER:		21586537

	BUSINESS ADDRESS:	
		STREET 1:		14 PLAZA DRIVE
		CITY:			LATHAM
		STATE:			NY
		ZIP:			12110
		BUSINESS PHONE:		5187981215

	MAIL ADDRESS:	
		STREET 1:		14 PLAZA DRIVE
		CITY:			LATHAM
		STATE:			NY
		ZIP:			12110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>an55676910-8ki.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ango="http://angiodynamics.com/20210129" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Cadwalader, Wickersham & Taft LLP
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2021 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_f1993659f03446b9824f6becb18ab322" contextRef="c20210129to20210129" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_97518236ccab4d9fa0e209b1136004fe" contextRef="c20210129to20210129">ANGIODYNAMICS INC</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_81b3ccde0c85439f82c68f05122d5984" contextRef="c20210129to20210129">0001275187</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_aceab718735d4536a70478a0269fb809" contextRef="c20210129to20210129">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ango-20210129.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20210129to20210129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-29</xbrli:startDate><xbrli:endDate>2021-01-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div><br />
      </div>

    </div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 18pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 18pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">
      <hr style="height: 1px; width: 10%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_67fbcba2a2e14e0380d8e7866beddf7a" contextRef="c20210129to20210129">8-K</ix:nonNumeric></div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the</div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">Securities Exchange Act of 1934</div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Date of Report (Date of earliest event reported): <span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_d9a38016eba34534a50f765d57e4943d" contextRef="c20210129to20210129" format="ixt:datemonthdayyearen">January 29, 2021</ix:nonNumeric></span></div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 18pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_97518236ccab4d9fa0e209b1136004fe">AngioDynamics, Inc.</span><br />
    </div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">(Exact Name of Registrant as Specified in Charter)</div>

    <table cellspacing="0" cellpadding="0" id="z9c11760bfbcb474bb23b739340a8eca0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_81c5a0b30204438cbef5b85c602137a8" contextRef="c20210129to20210129" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_810972cd8bb647629e130bcd27e0d52a" contextRef="c20210129to20210129">000-50761</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_b78ce3a87e714f3ba16df54db50863eb" contextRef="c20210129to20210129">11-3146460</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: top;">&#160;</td>

    <td style="width: 33.33%; vertical-align: top;">&#160;</td>

    <td style="width: 33.33%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">(State or Other Jurisdiction of Incorporation)</div>
          </td>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">(Commission File</div>
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Number)</div>
          </td>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">(IRS Employer</div>
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Identification No.)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 99.94%; vertical-align: top;" colspan="3">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_da007b33228547bf9e0df5fb71342eb1" contextRef="c20210129to20210129">14 Plaza Drive</ix:nonNumeric>
              <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_18ceccb51a9a409285a34b7bef2bdc75" contextRef="c20210129to20210129">Latham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_c703f87cbb1546ce895188d19f666e4b" contextRef="c20210129to20210129" format="ixt-sec:stateprovnameen">New York</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_034b6e1581014313b3a885661f44f489" contextRef="c20210129to20210129">12110</ix:nonNumeric></div>
          </td>

  </tr>

  <tr>

    <td style="width: 99.94%; vertical-align: top;" colspan="3">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">(Address of Principal Executive Offices) (Zip Code)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 99.94%; vertical-align: top;" colspan="3">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_127d7f6961f948f8a42e129735aeb280" contextRef="c20210129to20210129">518</ix:nonNumeric>)
              <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_7cda78c5542f49dfb5f57e910303dc21" contextRef="c20210129to20210129">795-1400</ix:nonNumeric></div>
          </td>

  </tr>

  <tr>

    <td style="width: 99.94%; vertical-align: top;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 99.94%; vertical-align: top;" colspan="3">
            <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">(Registrant&#8217;s telephone number, including area code)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; margin-top: 12pt; margin-bottom: 12pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing
      obligation of the registrant under any of the following provisions:</div>

    <table cellspacing="0" cellpadding="0" id="z4ac51367227e4e898fbcdd1d4f21b8d6" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 0.06%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_8796b1a446cb4b82bc29c1a595a7e8b9" contextRef="c20210129to20210129" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96.09%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 0.06%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_6fae92d1bd494b40b6245636a07e994e" contextRef="c20210129to20210129" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96.09%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 0.06%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_b9a187168c4d4e24937087fecda267c1" contextRef="c20210129to20210129" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96.09%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))</div>
          </td>

  </tr>

  <tr>

    <td style="width: 0.06%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_5ff8881df085486980ed873fd5544bf7" contextRef="c20210129to20210129" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96.09%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; margin-top: 12pt; margin-bottom: 12pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <table cellspacing="0" cellpadding="0" id="z1782ae11b04c44969a94cb7ced2d0a87" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 40.97%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><span style="text-decoration: underline;">Title of each class</span></div>
          </td>

    <td style="width: 22.57%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><span style="text-decoration: underline;">Trading Symbol(s)</span></div>
          </td>

    <td style="width: 36.46%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><span style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><span style="text-decoration: underline;">Name of each exchange on which</span></span><span style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><br />
              </span><span style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><span style="text-decoration: underline;">registered</span></span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.97%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_b2d3454ba1d6464c9762a2007005ad8b" contextRef="c20210129to20210129">Common Stock, par value $0.01 per share</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 22.57%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_c70aa5f9015e4df0ac2a92ee77dc98e0" contextRef="c20210129to20210129">ANGO</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 36.46%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><span style="-sec-ix-hidden:Fact_aceab718735d4536a70478a0269fb809">NASDAQ Global Select Market</span><br />
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: left; margin-top: 12pt; margin-bottom: 12pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
      Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div style="text-align: left; margin-top: 12pt; margin-bottom: 12pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_d656e1640dc54c609056266c40b5038b" contextRef="c20210129to20210129" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="text-align: left; margin-top: 12pt; margin-bottom: 12pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the
      extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-size: 12pt; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</span></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div>
        <div><br />
        </div>

      </div>

      <div style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div>
        <div><br />
        </div>

      </div>

    </div>

    <div><br />
    </div>

    <div style="text-align: left; margin-bottom: 8pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
      Officers; Compensatory Arrangements of Certain Officers.</div>

    <div style="text-align: justify; margin-bottom: 8pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><span style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">(e)</span> On January 29,
      2021, AngioDynamics, Inc. (&#8220;AngioDynamics&#8221;), entered into an Amended and Restated Change in Control Agreement with each of James C. Clemmer (President and Chief Executive Officer), Stephen A. Trowbridge (Executive Vice President and Chief Financial
      Officer), Scott Centea (Senior Vice President and General Manager, Vascular Interventions and Therapies), David D. Helsel (Senior Vice President of Global Operations and Research &amp; Development), Chad Thomas Campbell (Senior Vice President and
      General Manager, Vascular Access), and certain other members of AngioDynamics&#8217; executive leadership team (each, a &#8220;CIC Agreement&#8221;). Each CIC Agreement effectuates the changes previously approved to AngioDynamics&#8217; prior change in control agreements
      with each executive, as further described in AngioDynamics&#8217; definitive proxy statement, filed with the Securities and Exchange Commision on September 3, 2020, under &#8220;Executive Compensation &#8211; Compensation Discussion and Analysis &#8211; Potential Payments
      upon Termination or Change in Control &#8211; Change in Control Arrangements.&#8221;</div>

    <div style="text-align: justify; margin-bottom: 8pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Each CIC Agreement provides for an annual term expiring on December 31 of each year, subject to automatic renewals unless
      AngioDynamics provides an applicable executive with at least 60 days&#8217; written notice of non-renewal prior to expiration (except that, if a &#8220;change in control&#8221; occurs, then the term of the agreement is automatically extended for 24 calendar months
      after such &#8220;change in control&#8221;). If an applicable executive is terminated by AngioDynamics without &#8220;cause,&#8221; or resigns his or her employment for &#8220;good reason,&#8221; in each case during the term of the CIC Agreement and after a &#8220;change in control&#8221; (or,
      within three months prior to such &#8220;change in control,&#8221; if the executive can demonstrate that such termination without &#8220;cause&#8221; or event giving rise to &#8220;good reason&#8221; was undertaken at the request of a third party who undertook steps reasonably
      calculated to effectuate the &#8220;change in control,&#8221; or was otherwise in connection with or in anticipation of the &#8220;change in control&#8221;), then the CIC Agreement provides the executive with the following severance payments and benefits: (i) any earned but
      unpaid annual bonus for the fiscal year preceding the fiscal year of termination; (ii) a prorated annual bonus for the year of termination (based on the highest of the average bonuses awarded to the executive for (x) the 36 months preceding the
      termination, (y) the 3 fiscal years of AngioDynamics preceding the termination, and (z) the 36 months preceding the &#8220;change in control&#8221;, in each case disregarding any years in which the executive was not employed by AngioDynamics and annualizing
      bonuses for any partial year of employment); (iii) a lump sum cash severance payment equal to 1.5 times (2 times, for Mr. Clemmer) the sum of the executive&#8217;s base salary and target bonus; (iv) cashout of all earned but unused vacation leave; (v) an
      18-month (24-month, for Mr. Clemmer) COBRA subsidy; and (vi) accelerated vesting of any outstanding equity or equity-based awards (with any performance-based vesting requirements deemed achieved at the &#8220;target&#8221; level).</div>

    <div style="text-align: justify; margin-bottom: 8pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">These payments and benefits are subject to such executive&#8217;s execution of both a release of claims and a restrictive
      covenant agreement in favor of AngioDynamics (including a 24-month post-employment non-compete and non-solicit of customers, suppliers, other business relations, and employees; and a reciprocal, perpetual non-disparagement covenant). Each CIC
      Agreement also contains a customary &#8220;best-after-tax&#8221; Section 280G cutback in the event that any of the payments or benefits thereunder or otherwise payable to an executive are subject to the excise taxes imposed by Sections 280G and 4999 of the
      Internal Revenue Code of 1986, as amended.</div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div>
        <div><br />
        </div>

      </div>

      <div style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div>
        <div><br />
        </div>

      </div>

    </div>

    <div style="text-align: justify; margin-bottom: 8pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">The foregoing summary of the CIC Agreements does not purport to be complete and is qualified in its entirety by reference
      to the forms of CIC Agreement with Mr. Clemmer, attached as Exhibit 10.1 to this Current Report on Form 8-K, and each other executive officer, attached as Exhibit 10.2 to this Current Report on Form 8-K, and in each case incorporated herein by
      reference.</div>

    <div style="text-align: left; margin-bottom: 8pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">Item 9.01 - Financial Statements and Exhibits.</div>

    <div style="text-align: justify; margin-top: 12pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><span style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">(d)</span>&#160;<span style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-style: italic;">Exhibits</span>.</div>

    <table cellspacing="0" cellpadding="0" id="z0c0f9794897f4dab88e59c77030d2b80" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td rowspan="1" style="width: 15.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2.66%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 81.58%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 15.76%; vertical-align: top;">
            <div style="text-align: justify; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><span style="text-decoration: underline;">Exhibit No.</span></div>
          </td>

    <td style="width: 2.66%; vertical-align: top;">&#160;</td>

    <td style="width: 81.58%; vertical-align: top;">
            <div style="text-align: justify; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><span style="text-decoration: underline;">Description</span></div>
          </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 15.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2.66%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 81.58%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 15.76%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><a href="an55676910-ex10_1.htm">10.1</a></div>
          </td>

    <td style="width: 2.66%; vertical-align: top;">&#160;</td>

    <td style="width: 81.58%; vertical-align: top;">
            <div style="text-align: justify; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><a href="an55676910-ex10_1.htm">Amended


                and Restated Change in Control Agreement, by and between AngioDynamics, Inc. and James C. Clemmer.</a></div>
          </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 15.76%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2.66%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 81.58%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 15.76%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><a href="an55676910-ex10_2.htm">10.2</a></div>
          </td>

    <td style="width: 2.66%; vertical-align: top;">&#160;</td>

    <td style="width: 81.58%; vertical-align: top;">
            <div style="text-align: justify; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><a href="an55676910-ex10_2.htm">Form
                of Amended and Restated Change in Control Agreement with AngioDynamics, Inc.</a></div>
          </td>

  </tr>


</table>
    <div style="text-align: left; margin-top: 10pt;"><br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div>
        <div><br />
        </div>

      </div>

      <div style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div>
        <div><br />
        </div>

      </div>

    </div>

    <div style="text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">SIGNATURE</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
      on its behalf by the undersigned hereunto duly authorized.</div>

    <div><br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">


  <tr>

    <td valign="top" style="width: 50%; font-size: 12pt;">&#160;</td>

    <td valign="top" colspan="3" style="font-size: 12pt;"><strong><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: Arial,Helvetica,'sans-serif'; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">ANGIODYNAMICS, INC.</span><br />
              </strong></td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" rowspan="1" style="width: 50%; font-size: 12pt;">&#160;</td>

    <td valign="top" rowspan="1" colspan="3" style="font-size: 12pt;">(Registrant)<br />
            </td>

    <td valign="top" rowspan="1" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" rowspan="1" style="width: 50%; font-size: 12pt;">&#160;</td>

    <td valign="top" rowspan="1" colspan="3" style="font-size: 12pt;">&#160;</td>

    <td valign="top" rowspan="1" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" rowspan="1" style="width: 50%; font-size: 12pt;">&#160;</td>

    <td valign="top" rowspan="1" colspan="3" style="font-size: 12pt;">&#160;</td>

    <td valign="top" rowspan="1" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">
              <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; font-size: 12pt; text-align: left;">Date: February 3, 2021<br />
              </div>
            </td>

    <td valign="top" style="width: 3%; padding-bottom: 2px;">
              <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; font-size: 12pt; text-align: left;">By: </div>
            </td>

    <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; white-space: nowrap; font-size: 12pt; text-align: left;">/s/ Stephen A. Trowbridge<br />
            </td>

    <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%; font-size: 12pt;">&#160;</td>

    <td valign="top" style="width: 3%; font-size: 12pt;">&#160;</td>

    <td valign="bottom" align="left" style="width: 5%; font-size: 12pt; white-space: nowrap;">Name: <br />
            </td>

    <td valign="bottom" align="left" style="width: 30%; font-size: 12pt; white-space: nowrap;">Stephen A. Trowbridge <br />
            </td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%; font-size: 12pt;">&#160;</td>

    <td valign="top" style="width: 3%; font-size: 12pt;">&#160;</td>

    <td valign="top" style="width: 5%; font-size: 12pt;">Title:&#160;&#160; <br />
            </td>

    <td valign="top" style="width: 30%; font-size: 12pt;">Executive Vice President and Chief Financial Officer <br />
            </td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%; font-size: 12pt;">&#160;</td>

    <td valign="top" style="width: 3%; font-size: 12pt;">&#160;</td>

    <td valign="top" colspan="2" style="font-size: 12pt;">&#160;</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>


</table>
    </div>

    <br />
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>an55676910-ex10_1.htm
<DESCRIPTION>AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Cadwalader, Wickersham & Taft LLP
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left; color: #000000;">
  <div id="DSPFPageHeader">
    <div style="text-align: right;"><font style="font-weight: bold; font-size: 12pt;">Exhibit 10.1</font><br>
    </div>
  </div>
  <div><br>
  </div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">THIS AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Agreement</u></font>&#8221;), is made effective as of January 29, 2021 between AngioDynamics, Inc., a Delaware corporation (the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Company</u></font>&#8221;),





    and James C. Clemmer, an individual resident of New York (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Executive</u></font>&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">WHEREAS, the Company considers it essential to the best interests of its shareholders to foster the continued employment of
    key management personnel; and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">WHEREAS, the Board recognizes that, as is the case with many publicly held corporations, the possibility of a Change in
    Control exists and that such possibility, and the uncertainty and questions which it may raise among management, may result in the departure or distraction of management personnel to the detriment of the Company and its shareholders; and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">WHEREAS, the Board has determined that appropriate steps should be taken to reinforce and encourage the continued attention
    and dedication of members of the Company&#8217;s management, including the Executive, to their assigned duties without distraction in the face of potentially disturbing circumstances arising from the possibility of a Change in Control; and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">WHEREAS, the Company and the Executive previously entered into that certain Change in Control Agreement, dated as of April 1,
    2016 (as amended, modified, or supplemented from time to time, the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Original Agreement</u></font>&#8221;), and each of the Company and the Executive desire to amend and restate the
    Original Agreement in its entirety as set forth herein;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Company and the Executive
    hereby agree that the Original Agreement is hereby amended and restated in its entirety as follows:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">1.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Defined Terms</u></font>. The definitions of
    capitalized terms used in this Agreement are provided in the last Section hereof.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">2.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Term of Agreement</u></font>. The Term of
    this Agreement shall commence on the date hereof and shall continue in effect through December 31, 2021; provided, however, that effective January 1, 2022 and each January 1 thereafter, the Term that is then in effect shall automatically be extended
    for one additional year unless the Company has given at least sixty (60) days&#8217; written notice before the January 1 in question that the Term that is in effect at the time such notice is given will not be extended; and further provided, however, that if
    a Change in Control occurs during the Term, the Term shall expire no earlier than twenty-four (24) calendar months after the calendar month in which such Change in Control occurs. <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">Notwithstanding the foregoing, this Agreement shall terminate if the Executive ceases to be an employee of the Company and its subsidiaries for any reason prior to a Change in Control.</font><font style="font-size: 8pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">&#160; </font><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">However, anything in this Agreement (including the</font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <!--PROfilePageNumberReset%Num%2%Page % of 30 pages%-->
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">preceding sentence) to the contrary
      notwithstanding, i</font>f a Change in Control occurs and if, within three (3) months prior to the date on which such Change in Control occurs, the Executive&#8217;s employment with the Company is terminated by the Company without Cause or an event occurs
    that would, if it took place after the Change in Control, constitute Good Reason for termination of employment by the Executive, and if it is reasonably demonstrated by the Executive that such termination of employment by the Company or event
    constituting Good Reason for termination of employment by the Executive (a) was undertaken at the request of a third party who has taken steps reasonably calculated to effect the Change in Control, or (b) otherwise arose in connection with or in
    anticipation of the Change in Control, then for purposes of this Agreement such termination of employment by the Company without Cause or event constituting Good Reason shall be deemed to occur during the twenty-four (24) month period following the
    Change in Control and, if the Executive terminates the Executive&#8217;s employment for such Good Reason before the Change in Control, such termination of employment by the Executive shall likewise be deemed to occur during the twenty-four (24) month period
    following the Change in Control (it being understood that, in each case, the Review Period (as defined below) shall be deemed to commence on the date of the applicable Change in Control).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">3.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Company&#8217;s Covenants Summarized</u></font>. In
    order to induce the Executive to remain in the employ of the Company and in consideration of the Executive&#8217;s covenants set forth in Section 4 hereof, the Company agrees, under the conditions described herein, to pay the Executive the Severance Payments
    and the other payments and benefits described herein. Except as provided in Section 2, Section 6.3, Section 9.1, or Section 14.2 hereof, no amounts shall be payable under this Agreement unless the Executive&#8217;s employment with the Company terminates
    following a Change in Control and during the Term. This Agreement shall not be construed as creating an express or implied contract of employment enforceable against the Company nor, except as provided in Section 4 below, enforceable against the
    Executive, and, except as otherwise agreed in writing between the Executive and the Company, the Executive shall not have any right to be retained in the employ of the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">4.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>The Executive&#8217;s Covenants</u></font>. The
    Executive agrees to remain in the employ of the Company, subject to the terms and conditions of this Agreement, if a Potential Change in Control occurs during the Term and the Executive is then in the employ of the Company, until the earliest of (a)
    the date which is six (6) months after the date of such Potential Change in Control, (b) the date of a Change in Control, (c) the date of termination by the Executive of the Executive&#8217;s employment for Good Reason or by reason of death, Disability, or
    Retirement, or (d) the termination by the Company of the Executive&#8217;s employment for any reason; provided that Executive&#8217;s agreement to remain in the employ of the Company shall be subject to the condition that no adverse change occurs after the
    Potential Change in Control in the Executive&#8217;s title, duties, responsibilities, authority, reporting relationships, compensation, benefits, or indemnification rights.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">
    <div style="text-align: left; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">5.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Certain Compensation Other Than Severance Payments</u></font>.</div>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 2 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">5.1&#160; If the Executive&#8217;s employment shall be terminated for any reason following a Change in Control and during the Term, the
    Company shall pay the Executive&#8217;s full salary through the date of termination at the rate in effect immediately prior to the date of termination or, if higher, the rate in effect immediately prior to the first occurrence of an event or circumstance
    constituting Good Reason, together with all compensation and benefits payable to the Executive through the date of termination under the terms of the Company&#8217;s compensation and benefit plans, programs, and arrangements as in effect immediately prior to
    the date of termination or, if more favorable to the Executive, as in effect immediately prior to the first occurrence of an event or circumstance constituting Good Reason.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">5.2&#160; Subject to Section 6.1 hereof, if the Executive&#8217;s employment shall be terminated for any reason following a Change in
    Control and during the Term, the Company shall pay to the Executive the Executive&#8217;s normal post-termination compensation and benefits as such payments become due. Any such post-termination compensation and benefits shall be determined under, and paid
    in accordance with, the Company&#8217;s retirement, insurance and other compensation and benefit plans, programs, and arrangements as in effect immediately prior to the date of termination or, if more favorable to the Executive, as in effect immediately
    prior to the occurrence of the first event or circumstance constituting Good Reason.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">6.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Severance Payments</u></font>.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">6.1&#160; Subject to Section 6.2 and Section 6.3 hereof, if the Executive&#8217;s employment is terminated following a Change in Control
    and during the Term either by the Company or by the Executive, other than (a) by the Company for Cause, (b) by reason of death or Disability, or (c) by the Executive without Good Reason, (any such employment termination being hereafter sometimes
    referred to as a &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Compensable Termination</u></font>&#8221;), then the Company shall pay the Executive the amounts, and provide the Executive the benefits, described in this Section
    6.1 (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Severance Payments</u></font>&#8221;), in addition to any payments and benefits to which the Executive is entitled under Section 5 hereof. Notwithstanding the foregoing, the
    Executive shall not be eligible to receive any payment or benefit provided for in this Section 6.1 unless the Executive shall have executed a release substantially in the form of <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Exhibit





        A</u></font> hereto, and a covenant not to compete and other restrictions substantially in the form of <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Exhibit B</u></font> hereto, in each case within sixty (60) days
    following the date of the Compensable Termination (the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Review Period</u></font>&#8221;), and shall not have revoked said release.&#160; The Severance Payments are in lieu of any severance
    benefits that would otherwise be payable or provided pursuant to any severance plan or practice of the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(i) The Company shall pay the Executive, at the time provided in Section 6.2 below, the Executive&#8217;s annual
    bonus for the fiscal year of the Company preceding the fiscal year of the Company in which the Compensable Termination occurs, if unpaid at the time of the Compensable Termination, the amount of such bonus to be determined by the Compensation Committee
    of the Board on a basis no less favorable to the Executive than its bonus determinations</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 3 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt;">with respect to the Executive prior to the Change in Control, unless the Committee made no bonus determinations with respect
    to the Executive before the Change in Control, in which case on a basis no less favorable to the Executive than its bonus determinations with respect to other executives of comparable rank before the Change in Control.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(ii) The Company shall pay the Executive, at the time provided in Section 6.2 below, a prorated annual
    bonus for the fiscal year of the Company in which the Compensable Termination occurs, such prorated bonus to be determined by multiplying the &#8220;Applicable Average Bonus&#8221; as defined below in this subsection (ii) by a fraction, the numerator of which
    shall be the number of days elapsed in such fiscal year through (and including) the date on which the Compensable Termination occurs and the denominator of which shall be the number 365.&#160; For purposes of this Agreement, the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Applicable Average Bonus</u></font>&#8221; means the higher of (A) the average of all annual bonuses (including any deferred bonuses) awarded to the Executive during the thirty-six (36) months immediately
    preceding the Compensable Termination or, if the Executive was employed by the Company for less than thirty-six (36) months before the Compensable Termination, during the period of the Executive&#8217;s employment by the Company prior to the Compensable
    Termination (annualizing any bonus awarded for less than a full year of employment), or (B) the average of all annual bonuses (including any deferred bonuses) awarded to the Executive during the three (3) fiscal years of the Company that precede the
    fiscal year in which the Compensable Termination occurs or during the portion of such three fiscal years in which the Executive was employed by the Company (annualizing any bonus awarded for less than a full year of employment), or (C) the average of
    all annual bonuses (including any deferred bonuses) awarded to the Executive during the thirty-six (36) months preceding the date on which the Change in Control occurred or during the portion of such thirty-six (36) month period in which the Executive
    was employed by the Company (annualizing any bonus awarded for less than a full year of employment).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iii) The Company shall pay the Executive, at the time provided in Section 6.2 below, a lump sum cash
    payment equal to two (2) times the sum of (x) the Executive&#8217;s annual base salary at the rate in effect immediately prior to the Compensable Termination or, if higher, in effect immediately prior to the first occurrence of an event or circumstance
    constituting Good Reason (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Base Salary</u></font>&#8221;), and (y) the Executive&#8217;s annual cash bonus target at the rate in effect immediately prior to the Compensable Termination or,
    if higher, in effect immediately prior to the first occurrence of an event or circumstance constituting Good Reason (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Target Bonus</u></font>&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iv) The Company will pay the Executive for all earned but unused vacation leave at the time of the
    Compensable Termination.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(v) Subject to the Executive&#8217;s timely election and continued eligibility for continuation of coverage
    under the Consolidated Omnibus Budget</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 4 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt;">Reconciliation Act of 1985, as amended (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>COBRA</u></font>&#8221;),





    the Company shall continue the Executive&#8217;s participation in the Company&#8217;s group medical, dental, vision, and prescription drug coverage at no cost to the Executive and the Executive&#8217;s dependents for a period of twenty-four (24) months following the
    date of the Compensable Termination; provided, that, if such continuation is not permitted under the terms of the applicable Company benefit plan or program for all or any portion of such period, would result in the imposition of additional taxes or
    penalties (including, without limitation, under Section 105(h) of the Code), or would otherwise violate any applicable law, then the Company shall instead pay the Executive an additional cash amount per month during the period when such continuation
    would be so prohibited or subject to additional taxes or penalties equal to the total COBRA premium that would have been required to so continue the Executive&#8217;s (and the Executive&#8217;s dependents&#8217;) participation in such medical, dental, vision, and
    prescription drug programs.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(vi) Any stock options, restricted stock, restricted stock units, performance shares, performance share
    units, or other equity or equity-based awards granted to the Executive on or following the date of this Agreement, but prior to a Change in Control, shall vest in full, with any performance-based vesting requirements deemed achieved at the &#8220;target&#8221;
    level.&#160; For the avoidance of doubt, any equity or equity-based awards granted to the Executive prior to the date of this Agreement, or following the date of a Change in Control, shall be treated in accordance with their respective terms and conditions.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">6.2&#160; All payments and benefits
      to be made or provided pursuant to subsections (i) through (iv) of Section 6.1 above shall be made, and payments and benefits pursuant to subsection (v) shall commence, within thirty (30)&#160;calendar days after the date on which the release attached
      hereto as </font><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);"><u>Exhibit A</u></font><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);"> becomes fully
      effective and irrevocable in accordance with its terms; provided, that, if (x) such thirty (30) calendar day period, together with the Review Period, spans two (2) calendar years, such payments and benefits shall not be made or commence until the
      second (2</font><sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">) such calendar year, and (y) if, on the date of the Executive&#8217;s Separation from Service the
      Executive is a Specified Employee, and to the extent necessary to avoid the imposition of any additional taxes, interest, or penalties under Section 409A of the Code, such payments shall be made six months and one day after the date of the
      Compensable Termination (or, if earlier, the date of the Executive&#8217;s death), with any such payments that would have been made earlier absent this proviso made in a single lump sum on such date.</font>&#160; For purposes of the preceding sentence, a &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Specified Employee</u></font>&#8221; means a &#8220;specified employee&#8221; who is subject to the special rule set forth in subsection (a)(2)(B)(i) of Section 409A of the Code and the regulations
    thereunder (including, without limitation, Treasury Regulation section 1.409A-1(i)) with respect to such payments.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">6.3&#160; In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i)
    constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 5 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">imposed by Section 4999 of the Code (the &#8220;<font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Excise Tax</u></font>&#8221;),
    then Executive&#8217;s benefits under this Agreement shall be either</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt; text-indent: 36pt;">(i) delivered in full, or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt; text-indent: 36pt;">(ii) delivered as to such lesser extent which would result in no portion of such benefits being subject to
    the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, and local income taxes and the Excise Tax, results in the receipt by Executive on an after-tax basis, of the greatest amount of benefits,
    notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.&#160; If a reduction in severance and other benefits constituting &#8220;parachute payments&#8221; is necessary so that benefits are delivered to a lesser extent,
    reduction will occur in the following order: reduction of cash payments, cancellation of equity awards granted within the twelve (12) month period prior to a &#8220;change in control&#8221; (as determined under Code Section 280G) that are deemed to have been
    granted contingent upon the change in control (as determined under Code Section 280G), cancellation of accelerated vesting of equity awards, reduction of employee benefits.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Unless the Company and the Executive otherwise agree in writing, any determination required under this Section shall be made in writing by the
    Company&#8217;s independent public accountants (the &#8220;<font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Accountants</u></font>&#8221;), whose determination shall be conclusive and binding upon Executive and the Company for all purposes.&#160;
    For purposes of making the calculations required by this Section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of
    Section 280G and 4999 of the Code.&#160; The Company and the Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section.&#160; The Company shall bear all
    costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">7.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Payments During Dispute</u></font>. Any
    payments to which the Executive may be entitled under this Agreement, including, without limitation, under Sections 5 and 6 hereof, shall be made forthwith on the applicable date(s) for payment specified in this Agreement.&#160; If for any reason the amount
    of any payment due to the Executive cannot be finally determined on that date, such amount shall be estimated on a good faith basis by the Company and the estimated amount shall be paid no later than ten (10) days after such date.&#160; As soon as
    practicable thereafter, the final determination of the amount due shall be made and any adjustment requiring a payment to or from the Executive shall be made as promptly as practicable.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">8.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Mitigation</u></font>. The Company agrees
    that, if the Executive&#8217;s employment with the Company terminates during the Term, the Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable or benefits to be provided to the Executive by the Company
    pursuant to Section 6 hereof or any other provision of this Agreement. Further, the amount of any payment or benefit</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 6 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">provided for in this Agreement shall not be reduced (a) by any compensation earned by the Executive as the result of employment by another
    employer, (b) by retirement benefits, (c) by offset against any amount claimed to be owed by the Executive to the Company, or (d) otherwise.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">9.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Successors; Binding Agreement</u></font>.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">9.1&#160; In addition to any obligations imposed by law upon any successor to the Company, the Company will require any successor
    (whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to perform the Company&#8217;s obligations under this Agreement in the same
    manner and to the same extent that the Company would be required to perform if no such succession had taken place. Failure of the Company to obtain such assumption and agreement prior to the effectiveness of any such succession during the Term shall be
    a breach of this Agreement and shall entitle the Executive to compensation from the Company in the same amount and on the same terms as the Executive would be entitled to hereunder if the Executive were to terminate the Executive&#8217;s employment for Good
    Reason after a Change in Control and during the Term, except that, for purposes of implementing the foregoing, the date on which any such succession becomes effective during the Term shall be deemed the date of the Compensable Termination.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">9.2&#160; This Agreement shall inure to the benefit of and be enforceable by the Executive&#8217;s personal or legal representatives,
    executors, administrators, successors, heirs, distributees, devisees, and legatees. If the Executive shall die while any amount would still be payable to the Executive hereunder (other than amounts which, by their terms, terminate upon the death of the
    Executive) if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives, or administrators of the Executive&#8217;s estate.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">10. <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Notices</u></font>. For the purpose of this
    Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail, return receipt requested, postage prepaid,
    addressed, if to the Executive, to the Executive&#8217;s most recent address shown on the books and records of the Company at the time notice is given and, if to the Company, to the address set forth below, or to such other address as either party may have
    furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon actual receipt:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">To the Company:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">AngioDynamics, Inc.</div>
  <div style="text-align: justify; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">14 Plaza Drive</div>
  <div style="text-align: justify; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">Latham, NY 12110</div>
  <div style="text-align: justify; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">Attention: Office of the General Counsel</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 7 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">11.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Miscellaneous</u></font>. No provision of
    this Agreement may be modified, waived, or discharged unless such waiver, modification, or discharge is agreed to in writing and signed by the Executive and such officer as may be specifically designated by the Board. No waiver by either party hereto
    at any time of any breach by the other party hereto of, or of any lack of compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at
    the same or at any prior or subsequent time. <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">This Agreement constitutes the entire agreement of the parties concerning the specific subject matter addressed
      by this Agreement and supersedes all prior agreements addressing the terms and conditions contained herein (including, without limitation, the Original Agreement).&#160; </font>The validity, interpretation, construction, and performance of this Agreement
    shall be governed by the laws of the State of New York. All references to sections of the Code or the Exchange Act shall be deemed also to refer to any successor provisions to such sections and to IRS or SEC regulations and official guidance published
    thereunder. Any payments provided for hereunder shall be subject to any applicable withholding required under federal, state, or local law and any additional withholding to which the Executive has agreed. The obligations of the Company and the
    Executive under this Agreement which by their nature may require either partial or total performance after the expiration of the Term (including, without limitation, those under Sections 6 and 7 hereof) shall survive such expiration.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">12.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Validity</u></font>. The invalidity or
    unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">13.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Counterparts</u></font>. This Agreement may
    be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Settlement of Disputes; Arbitration</u></font>.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.1&#160; All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board and
    shall be in writing. Any denial by the Board of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon.
    The Board shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim and shall further allow the Executive to appeal to the Board a decision of the Board within sixty (60) days after notification by the Board
    that the Executive&#8217;s claim has been denied.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.2&#160; Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by
    arbitration in the Albany, New York metropolitan area in accordance with the employment dispute resolution rules of the American Arbitration Association then in effect. The arbitrator shall have the authority to require that the Company reimburse the
    Executive for the payment of all or any portion of the legal fees and expenses incurred by the Executive in connection with such dispute or</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 8 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;">controversy. Judgment may be entered on the arbitrator&#8217;s award in any court having jurisdiction.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.3&#160; The Company agrees to use commercially reasonable efforts to administer this Agreement, and operate any deferred
    compensation plans in which the Executive participates from time to time that are aggregated with this Agreement or with any payment or benefit provided by this Agreement for purposes of Section 409A of the Code (e.g., account balance plans, nonaccount
    balance plans, separation pay plans, and plans that are neither account balance nor nonaccount balance plans), in good faith compliance with Code Section 409A to the extent necessary to avoid inclusion of any amounts of benefits payable hereunder in
    the Executive&#8217;s income pursuant to Section 409A(a)(1)(A) of the Code or the imposition of any additional taxes, interest, or penalties under Section 409A of the Code.&#160; Notwithstanding the foregoing, the Executive shall be solely liable for any
    additional taxes, interest, or penalties imposed under Section 409A of the Code, and the Company shall not be required to indemnify the Executive for any such amounts.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.4&#160; If there shall be any dispute between the Company and the Executive (i) in the event of any termination of the
    Executive&#8217;s employment by the Company, whether such termination was for Cause, or (ii) in the event of any termination of employment by the Executive, whether Good Reason existed, then, unless and until there is a final, non-appealable judgment by a
    court of competent jurisdiction declaring that such termination was for Cause or that the determination by the Executive of the existence of Good Reason was not made in good faith, the Company shall pay all amounts, and provide all benefits, to the
    Executive and/or the Executive&#8217;s family or other beneficiaries, as the case may be, that the Company would be required to pay or provide pursuant to Section 6 as though such termination were by the Company without Cause, or by the Executive with Good
    Reason; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>provided</u></font>, <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>however</u></font>, that the Company shall not be required to pay any
    disputed amount pursuant to this paragraph except upon receipt of an undertaking by or on behalf of the Executive to repay all such amounts to which the Executive is ultimately adjudged by such court not to be entitled.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">15.&#160;&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Definitions</u></font>. For purposes of
    this Agreement, the following terms shall have the meanings indicated below:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(A)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Affiliate</u></font>&#8221; shall have the meaning
    set forth in Rule 12b-2 promulgated under Section 12 of the Exchange Act.</div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(B)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Applicable Average Bonus</u></font>&#8221; shall have
    the meaning set forth in subsection (ii) of Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(C)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Base Salary</u></font>&#8221; shall have the
    meaning set forth in subsection (iii) of Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(D)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Beneficial Owner</u></font>&#8221; shall have the
    meaning set forth in Rule 13d-3 under the Exchange Act.</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 9 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">&#160;(E)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Board</u></font>&#8221; shall mean the Board of
    Directors of the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">&#160;(F)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Cause</u></font>&#8221; for termination by the
    Company of the Executive&#8217;s employment shall mean (i) the willful and persistent failure by the Executive to substantially perform the Executive&#8217;s duties with the Company as such duties were in effect prior to any change therein constituting Good Reason
    (other than any such failure resulting from the Executive&#8217;s incapacity due to physical or mental illness, Disability (as defined in the Employment Agreement, by and between the Executive and the Company, dated as of April 1, 2016, as amended from time
    to time), or any such failure after the occurrence of an event constituting Good Reason for resignation by the Executive) after a written demand for substantial performance is delivered to the Executive by the Board, which demand specifically
    identifies the manner in which the Board believes that the Executive has not substantially performed the Executive&#8217;s duties, provided that such failure will constitute Cause only if it remains uncured for more than thirty (30) days following receipt by
    the Executive of such written demand from the Board; (ii) the engaging by the Executive in willful and persistent conduct which is demonstrably and materially injurious to the Company or its subsidiaries, monetarily or otherwise, provided that such
    conduct will constitute Cause only if it remains uncured for more than thirty (30) days following receipt by the Executive of a written demand from the Board to cease such conduct; or (iii) the Executive&#8217;s conviction of (a) a felony or (b) a crime
    involving fraud, dishonesty, or moral turpitude. For purposes of clauses (i) and (ii) of this definition, no act, or failure to act, on the Executive&#8217;s part shall be deemed &#8220;willful&#8221; unless done, or omitted to be done, by the Executive not in good
    faith and without reasonable belief that the Executive&#8217;s act, or failure to act, was in the best interest of the Company.&#160; The Company shall notify the Executive in a writing that specifically identifies the provision of the Cause definition that
    applies, and must provide the Executive a reasonable period (not less than thirty (30) days) in which to respond and/or cure such alleged grounds to the Board&#8217;s satisfaction; and provided further that the Executive shall thereafter be granted the
    opportunity within a reasonable period (not more than thirty (30) days) to appear before the Board, with counsel, to address any such claimed grounds, during which period the Company may not implement such termination. Any purported termination of
    employment by the Company for Cause which does not satisfy the applicable requirements of this Section 15(F) shall be conclusively deemed to be a termination of employment by the Company without Cause for purposes of this Agreement. To the extent that
    this definition of &#8220;Cause&#8221; is more beneficial to the Executive than any definition of &#8220;Cause&#8221; in any granting document relating to his stock options, restricted stock units, or performance shares, the Board shall take any such necessary steps to ensure
    that this definition, and not any more restrictive definition contained in any granting document, shall apply.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">&#160;(G)&#160; A &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Change in Control</u></font>&#8221; shall mean
    that any of the following events has occurred:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(i) any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company
    representing more than fifty percent (50%) of the combined voting power of the Company&#8217;s then outstanding securities,</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 10 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt;">excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (A) of
    paragraph (iii) below; or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(ii) the following individuals cease for any reason to constitute a&#160; majority of the number of directors
    serving on the Board: individuals who, at the beginning of any period of two (2) consecutive years or less (not including any period prior to the date of this Agreement), constitute the Board and any new director (other than a director whose initial
    assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for
    election by the Company&#8217;s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of such period or whose appointment, election, or nomination for
    election was previously so approved or recommended; or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iii) there is consummated a merger or consolidation of the Company or any Subsidiary with any other
    corporation, other than (A) a merger or consolidation which would result in the voting securities of the Company&#160; &#160;&#160; outstanding immediately prior to such merger or consolidation continuing to&#160; &#160;&#160; represent (either by remaining outstanding or by being
    converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, at least sixty
    percent (60%) of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (B) a merger or consolidation effected to implement a
    recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the
    Company&#8217;s then outstanding securities; or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iv) the shareholders of the Company approve a plan of complete liquidation or dissolution of the Company
    or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets, other than a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets to an entity, at
    least sixty percent (60%) of the combined voting power of the voting securities of which are owned by shareholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(H)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>COBRA</u></font>&#8221; shall have the meaning set
    forth in subsection (v) of Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(I)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Code</u></font>&#8221; shall mean the Internal
    Revenue Code of 1986, as amended from time to time.</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 11 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(J)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Company</u></font>&#8221; shall mean
    AngioDynamics, Inc. and, except in determining under Section 15(G) hereof whether or not any Change in Control of the Company has occurred, shall include any successor to its business and/or assets which assumes and agrees to perform this Agreement by
    operation of law, or otherwise.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(K)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Compensable Termination</u></font>&#8221; shall
    have the meaning set forth in Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(L)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Disability</u></font>&#8221; shall be deemed the
    reason for the termination by the Company of the Executive&#8217;s employment, if, as a result of the Executive&#8217;s incapacity due to physical or mental illness, the Executive shall have been absent from the full-time performance of the Executive&#8217;s duties with
    the Company for a period of six (6) consecutive months or for six (6) non-consecutive months within any period of twelve (12) consecutive months.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(M)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Exchange Act</u></font>&#8221; shall mean the
    Securities Exchange Act of 1934, as amended from time to time.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(N)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Executive</u></font>&#8221; shall mean the
    individual named in the first paragraph of this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(O)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Good Reason</u></font>&#8221; for termination by
    the Executive of the Executive&#8217;s employment shall mean the occurrence (without the Executive&#8217;s express written consent) after any Change in Control, of any one of the following acts by the Company, or failures by the Company to act, unless, in the case
    of any act or failure to act described in paragraph (i), (iii), (iv), or (vi) below, such act or failure to act is corrected within thirty (30) calendar days after the Company&#8217;s receipt of written notice thereof given by the Executive within ninety
    (90) calendar days of such act or failure to act:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(i) the assignment to the Executive of any duties inconsistent with the Executive&#8217;s status or position in
    the Company immediately prior to the Change in Control, or a substantial adverse alteration in the nature, status, or scope of the Executive&#8217;s responsibilities or authority from the Executive&#8217;s responsibilities or authority immediately prior to the
    Change in Control, or a reduction in the Executive&#8217;s title;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(ii) a reduction by the Company in the Executive&#8217;s Base Salary or Target Bonus, in each case as in effect
    on the date of this Agreement or as they may be increased from time to time;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(iii) a significant reduction in compensation, benefits, or reimbursements provided under any employment,
    compensation, employee benefit, or reimbursement plan or program in which the Executive is a participant which is not replaced with substantially equivalent compensation, benefits, or</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 12 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt;">reimbursements under another plan, program, or arrangement at substantially the same cost (if any) to the Executive;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iv) the Company fails to pay or provide any amount or benefit that the Company is obligated to pay or
    provide under this Agreement or any other employment, compensation, benefit, or reimbursement plan, agreement, or arrangement of the Company to which the Executive is a party or in which the Executive participates;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(v)&#160;&#160; the relocation of the Executive&#8217;s principal place of employment to a location which increases the
    Executive&#8217;s one-way commuting distance by more than forty (40) miles, or the Company&#8217;s requiring the Executive to travel on business other than to an extent substantially consistent with the Executive&#8217;s business travel obligations prior to the Change
    in Control;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(vi)&#160;&#160; a significant adverse change occurs, whether of a quantitative or qualitative nature, in the
    indemnification protection provided to the Executive for acts and omissions arising out of the Executive&#8217;s service on behalf of the Company or any other entity at the request of the Company;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(vii) a material breach by the Company of any material provision of this Agreement; or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(viii) the Company fails to obtain the assumption of this Agreement pursuant to Section&#160;9.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">The Executive&#8217;s right to terminate the Executive&#8217;s employment for Good Reason shall not be affected by the Executive&#8217;s incapacity due to
    physical or mental illness. The Executive&#8217;s continued employment shall not constitute consent to, or a waiver of rights with respect to, any act or failure to act constituting Good Reason hereunder.&#160; To constitute Good Reason, the Executive must
    terminate the Executive&#8217;s employment with the Company within ninety (90) calendar days following the date that such event giving rise to Good Reason occurs (or, if later, the date of expiration of any applicable period that the Company has to cure such
    event).&#160; To the extent that this definition of &#8220;Good Reason&#8221; is more beneficial to Executive than any definition of &#8220;Good Reason&#8221; in any granting document relating to his stock options, restricted stock units, or performance shares, the Board shall
    take any such necessary steps to ensure that this definition, and not any more restrictive definition contained in any granting document, shall apply.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(P)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Person</u></font>&#8221; shall have the meaning
    given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its Subsidiaries, (ii) a trustee or other fiduciary holding securities under an
    employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the shareholders of the</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 13 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Company in substantially the same proportions as their ownership of stock of the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(Q)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Potential Change in Control</u></font>&#8221;
    shall be deemed to have occurred if the event set forth in any one of the following paragraphs shall have occurred:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(i) the Company enters into an agreement, the consummation of which would result in the occurrence of a
    Change in Control;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(ii) the Company or any Person publicly announces an intention to take or to consider taking actions
    which, if consummated, would constitute a Change in Control;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iii) any Person becomes the Beneficial Owner, directly or indirectly, of securities of the Company
    representing fifteen percent (15%) or more of either the then outstanding shares of common stock of the Company or the combined voting power of the Company&#8217;s then outstanding securities (not including in the securities beneficially owned by such Person
    any securities acquired directly from the Company or its Affiliates); or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iv) the Board adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change
    in Control has occurred.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(R) &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Retirement</u></font>&#8221; shall be deemed the
    reason for the termination by the Executive of the Executive&#8217;s employment if such employment is terminated in accordance with the Company&#8217;s retirement policy (if any), including early retirement, generally applicable to its salaried employees.</div>
  <div style="text-align: justify; margin-top: 12pt; color: rgb(0, 0, 0); font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(S)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Review Period</u></font>&#8221;
    shall have the meaning set forth in Section 6.1 hereof.</div>
  <div style="text-align: justify; margin-top: 12pt; color: rgb(0, 0, 0); font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(T)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Separation from Service</u></font>&#8221;
    means termination of employment with the Company. However, the Executive shall not be deemed to have a Separation from Service unless such Separation from Service also constitutes a &#8220;separation from service&#8221; under Section 409A and the regulations
    promulgated thereunder.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(U)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Severance Payments</u></font>&#8221; shall have
    the meaning set forth in Section 6.1 hereof.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(V) &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Subsidiary</u></font>&#8221; means a corporation or
    other form of business association of which shares (or other ownership interests) having more than fifty percent (50%) of the voting power are owned or controlled, directly or indirectly, by the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(W)&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Target Bonus</u></font>&#8221; shall have the
    meaning set forth in subsection (iii) of Section 6.1.</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 14 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(X)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Term</u></font>&#8221; shall mean the period of
    time described in Section 2 hereof (including any extension or continuation described therein).</div>
  <div style="margin-top: 12pt;"><br>
  </div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">[Remainder of page intentionally left blank. Signature page follows.]</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 15 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date and year first above written.</div>
  <div style="text-align: justify; margin-top: 12pt;"><br>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">ANGIODYNAMICS, INC.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">By: __<font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>/s</u></font><u>/ Stephen A. Trowbridge</u>_________</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Name: Stephen A. Trowbridge</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Title:&#160;&#160; EVP and CFO</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>/s</u></font><u>/ James C. Clemmer</u>________________</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">James C. Clemmer</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 16 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-variant: small-caps; font-weight: bold;"><u>Exhibit A</u></div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">ANGIODYNAMICS, INC.</div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;"><u>RELEASE OF CLAIMS</u></div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">This Release of Claims (&#8220;Agreement&#8221;) is made by and between AngioDynamics, Inc. (the &#8220;Company&#8221;), and James C. Clemmer (&#8220;Executive&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">WHEREAS, Executive has agreed to enter into a release of claims in favor of the Company upon certain events specified in the Amended and
    Restated Change in Control Agreement by and between Company and Executive, as amended (the &#8220;Severance Agreement&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">NOW THEREFORE, in consideration of the mutual promises made herein, Executive hereby agrees as follows:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">1.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Termination</u></font>. Executive&#8217;s
    employment from the Company terminated on [DATE].</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">2.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Confidential Information</u></font>.
    Executive shall continue to maintain the confidentiality of all confidential and proprietary information of the Company and shall continue to comply with the terms and conditions of the Proprietary Information and Nondisclosure Agreement between
    Executive and the Company (the &#8220;Confidentiality Agreement&#8221;), as well as <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Exhibit B</u></font> to the Severance Agreement. Executive shall return all the Company property and
    confidential and proprietary information in Executive&#8217;s possession to the Company on the Effective Date of this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">3.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Payment of Salary</u></font>. Executive
    acknowledges and represents that the Company has paid all salary, wages, bonuses, accrued vacation, commissions, and any and all other benefits due to Executive.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">4.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Release of Claims</u></font>. Except as set
    forth in the last paragraph of this Section 4, Executive agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company.&#160; Executive, on behalf of himself or herself, and Executive&#8217;s
    respective heirs, family members, executors, and assigns, hereby fully and forever releases the Company and its past, present, and future officers, agents, directors, employees, investors, shareholders, administrators, affiliates, divisions,
    subsidiaries, parents, predecessor and successor corporations, and assigns, from, and agrees not to sue or otherwise institute or cause to be instituted any legal or administrative proceedings concerning any claim, duty, obligation, or cause of action
    relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive may possess arising from any omissions, acts, or facts that have occurred up until and including the Effective Date of this Agreement
    including, without limitation:</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 17 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(a) any and all claims relating to or arising from Executive&#8217;s employment relationship with the Company and the termination
    of that relationship;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(b) any and all claims relating to, or arising from, Executive&#8217;s right to purchase, or actual purchase of shares of stock of
    the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(c) any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination;
    breach of contract, both express and implied; breach of a covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation;
    negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; and conversion;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(d) any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of
    the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974, and The Worker
    Adjustment and Retraining Notification Act;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(e) any and all claims for violation of the federal, or any state, constitution;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(g) any and all claims for attorneys&#8217; fees and costs.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Notwithstanding anything to the contrary in this Section 4, the foregoing release does not impair, release, or otherwise modify (A) any
    obligation of the Company to Executive pursuant to any rights to the severance and other benefits payable under the Severance Agreement; or (B) rights to indemnification pursuant to Section 4.5 of the Employment Agreement, by and between the Executive
    and the Company, dated as of April 1, 2016, as amended from time to time (the &#8220;Employment Agreement&#8221;); or (C) rights to enforce this Agreement; or (D) rights to any vested Long Term Incentives under Section 3.3 of the Employment Agreement in accordance
    with governing award agreement and plan. Executive agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">5.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Acknowledgment of Waiver of Claims under ADEA</u></font>.
    Executive acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;ADEA&#8221;) and that this waiver and release is knowing and voluntary. Executive and the Company agree that
    this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement.&#160; Executive acknowledges that the consideration given for this waiver and release Agreement is in addition to
    anything of value to which</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 18 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Executive was already entitled.&#160; Executive further acknowledges that Executive has been advised by this writing that (a) Executive should
    consult with an attorney prior to executing this Agreement; (b) Executive has at least [twenty-one (21)][forty-five (45)] days within which to consider this Agreement; (c) Executive has seven (7) days following the execution of this Agreement to revoke
    the Agreement; (d) this Agreement shall not be effective until the revocation period has expired (provided Executive has not revoked this Agreement); and (e) nothing in this Agreement prevents or precludes Executive from challenging or seeking a
    determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties or costs for doing so, unless specifically authorized by federal law. Any revocation should be in writing and delivered to
    [HR Contact Name] at the Company by close of business on the seventh (7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day from the date that Executive signs this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">6.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Pending or Future Lawsuits</u></font>.
    Executive represents that Executive has no lawsuits, claims, or actions pending in Executive&#8217;s name, or on behalf of any other person or entity, against the Company or any other person or entity referred to herein. Executive also represents that
    Executive does not intend to bring any claims on Executive&#8217;s own behalf or on behalf of any other person or entity against the Company or any other person or entity referred to herein.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">7.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Application for Employment</u></font>.
    Executive understands and agrees that, as a condition of this Agreement, Executive shall not be entitled to any employment with the Company, its subsidiaries, or any successor, and Executive hereby waives any right, or alleged right, of employment or
    re-employment with the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">8.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Cooperation</u></font>. Executive agrees
    that Executive will not counsel or assist any attorneys or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against the Company and/or any officer, director,
    employee, agent, representative, shareholder, or attorney of the Company, unless under a subpoena or other court order to do so.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">9.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Cooperation with Company</u></font>.
    Executive agrees to cooperate, at the request of the Company, in the defense and/or prosecution of any charges, claims, investigations (internal or external), administrative proceedings, and/or lawsuits relating to matters occurring during or relating
    to Executive&#8217;s period of employment about which Executive may have relevant information. Executive shall further reasonably cooperate with regard to the transition of Executive&#8217;s job duties and business relationships. Executive agrees to respond to
    reasonable requests for information from the Company in a timely manner.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">10.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Admission of Liability</u></font>. No
    action taken by the Company, either previously or in connection with this Agreement shall be deemed or construed to be (a) an admission of the truth or falsity of any claims heretofore made or (b) an acknowledgment or admission by the Company of any
    fault or liability whatsoever to Executive or to any third party.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">11.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Costs</u></font>. Executive shall bear
    Executive&#8217;s own costs, expert fees, attorneys&#8217; fees, and other fees incurred in connection with executing this Agreement.</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 19 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">12.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Authority</u></font>. Executive represents
    and warrants that Executive has the capacity to act on Executive&#8217;s own behalf and on behalf of all who might claim through Executive to bind them to the terms and conditions of this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">13.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Representations</u></font>. Executive
    represents that Executive has had the opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the provisions of this Agreement.&#160; Executive has not relied upon any representations or statements made by the
    Company which are not specifically set forth in this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Severability</u></font>. In the event that
    any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">15.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Entire Agreement</u></font>. This Agreement,
    along with the Confidentiality Agreement, the Severance Agreement, and Executive&#8217;s written equity compensation agreements with the Company, represents the entire agreement and understanding between the Company and Executive concerning Executive&#8217;s
    separation from the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">16.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Oral Modification</u></font>. This
    Agreement may only be amended in writing signed by Executive and a duly authorized officer of the Company (other than Executive).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">17.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Governing Law</u></font>. This Agreement
    shall be governed by the internal substantive laws, but not the choice of law rules, of the State of New York.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">18. <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Effective Date</u></font>. Executive has
    seven (7) days after Executive signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Executive signed this Agreement (&#8220;Effective Date&#8221;), provided that Executive has not timely revoked this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">19.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Voluntary Execution of Agreement</u></font>.
    This Agreement is executed voluntarily and without any duress or undue influence on the part of Executive, with the full intent of releasing all claims. Executive acknowledges that:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(a) Executive has read this Agreement;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(b) Executive had the opportunity of being represented in the preparation, negotiation, and execution of this Agreement by
    legal counsel of Executive&#8217;s own choice or Executive has voluntarily declined to seek such counsel;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(c) Executive understands the terms and consequences of this Agreement and of the releases it contains;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(d) Executive is fully aware of the legal and binding effect of this Agreement.</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 20 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">IN WITNESS WHEREOF, Executive has have executed this Agreement on the date set forth below.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Dated:&#160; [MONTH], 20___</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">By:&#160;&#160;&#160;&#160;&#160; __________________________<br>
  </div>
  <div style="text-align: left; text-indent: 36pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">James C. Clemmer</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 21 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-variant: small-caps; font-weight: bold;"><u>Exhibit B</u></div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">ANGIODYNAMICS, INC.</div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;"><u>NON-COMPETITION AND NON-SOLICITATION AGREEMENT</u></div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">This Non-Competition and Non-Solicitation Agreement (&#8220;Agreement&#8221;) is made by and between AngioDynamics, Inc. (the &#8220;Company&#8221;), and James C.
    Clemmer (&#8220;Executive&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">WHEREAS, Executive has agreed to enter into a non-competition and non-solicitation agreement in favor of the Company upon certain events
    specified in the Amended and Restated Change in Control Agreement by and between the Company and Executive, as amended (the &#8220;Severance Agreement&#8221;); and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">WHEREAS, in consideration for the Company&#8217;s promises and covenants contained in the Severance Agreement, Executive agrees to be bound by the
    terms of this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">NOW THEREFORE, in consideration of the mutual promises made herein and in the Severance Agreement, Executive and the Company hereby agree as
    follows:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z5b8a6043680542199f0700b16bc79de6">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">1.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Terms used in this Agreement</font>:</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">a.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>AngioDynamics</u></font> means AngioDynamics, Inc., its successors or
              assigns, and any of their existing and future divisions, subsidiaries, and affiliates.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">b.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Confidential Information</u></font> means all trade secrets, proprietary
              information, know-how, and confidential information disclosed to Executive or known by Executive as a result of Executive&#8217;s employment by AngioDynamics, not generally known in the trade or industry in which AngioDynamics is engaged, about
              AngioDynamics&#8217; business operations, customers, suppliers, products, processes, machines, systems, and services, including research, development, manufacturing, purchasing, finance, data processing, engineering, marketing, designs, concepts,
              know-how, merchandising, and selling, and corresponding information about the products, processes, machines, and services of AngioDynamics, acquired by Executive during Executive&#8217;s employment by </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
      </div>
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 22 of 30 pages</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div id="DSPFPageHeader">
        <div><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">AngioDynamics. The fact that information is not patentable or copyrightable shall not affect its status as Confidential Information.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">c.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Conflicting Product</u></font> means any product, process, machine, or
              service of any person or organization other than AngioDynamics, whether now existing or hereafter developed: (a) which is identical to, substantially the same as, an adequate substitute for, resembles, or competes with a product, process,
              machine, system, or service upon or with which Executive worked during Executive&#8217;s term of employment with AngioDynamics or about which Executive acquired Confidential Information; or (b) whose use or marketability could be enhanced by
              application to it of Confidential Information to which Executive had access during Executive&#8217;s employment with AngioDynamics; or (c) which is (or could reasonably be anticipated to be) marketed</div>
          </td>
        </tr>

    </table>
  </div>
  <br>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 23 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;">
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z3c9758b5863b4898acc8c5c634d377e4">

        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">or distributed in such a manner and in such a geographic area as to actually compete with such a product, process, machine, or service of AngioDynamics.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">d.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Conflicting Organization</u></font> means any person or organization, which
              is now or hereafter engaged directly or indirectly in research on or the acquisition, development, production, distribution, marketing, providing, or selling of a Conflicting Product.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">e.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Terms not defined herein shall have the meaning ascribed to such terms in the Severance Agreement.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">2.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Non-Competition</font>.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">a.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">For a period of twenty four (24) months after termination of Executive&#8217;s employment with AngioDynamics pursuant to the Severance Agreement, Executive
              will not render services, directly or indirectly, to any Conflicting Organization.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">However, notwithstanding the foregoing, Executive understands that he/she may work for a Conflicting Organization whose business is diversified, provided
              Executive&#8217;s work for the Conflicting Organization does not involve selling, managing, overseeing, developing, creating, promoting, servicing, involvement in the financing and/or accounting of, or other responsibility for any Conflicting
              Product on which Executive worked or gained Confidential Information during the last two (2) years of Executive&#8217;s employment with AngioDynamics. Prior to accepting such employment, the Conflicting Organization and Executive must provide
              written assurances reasonably satisfactory to AngioDynamics (as determined in good </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
      </div>
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 24 of 30 pages</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div id="DSPFPageHeader">
        <div><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">faith), that Executive will not render services, directly or indirectly, in connection with any Conflicting Product on which Executive worked or gained
              Confidential Information during the last two (2) years of Executive&#8217;s employment with AngioDynamics and that necessary safeguards have been put in place to ensure that this does not happen.&#160; This section shall be construed in a manner to give
              effect to the restrictions contained herein to the maximum extent permitted by applicable law.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">b.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">The restrictions set forth in Section 2(a) apply in the United States and in any foreign country or foreign territory where AngioDynamics produces,
              sells, or markets its goods and services.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">3.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Non-Solicitation</font>.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">a.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Business Relations</font>. Executive agrees that for a
              period of twenty four (24) months after the termination of Executive&#8217;s employment with AngioDynamics pursuant to the Severance Agreement, Executive will not solicit, induce, attempt to induce, appropriate, direct, or assist another to
              appropriate or direct, or provide any services to any current customer, supplier, licensee, or other business relation (defined as any customer, supplier, licensee, or other business relation of AngioDynamics with whom Executive had dealings
              and/or for whom Executive performed services at any time during the last two (2) years of Executive&#8217;s employment with AngioDynamics) to</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 25 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;">
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z8975c5fffb48453a86a2d9f7367cd00c">

        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">cease doing business with AngioDynamics (including, without limitation, making any negative statements or communications concerning AngioDynamics or any
              of its directors, officers, or employees).</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">b.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Employees</font>. Executive agrees that for a period of
              twenty four (24) months after the termination of Executive&#8217;s employment with AngioDynamics pursuant to the Severance Agreement, Executive will not solicit, interfere with, encourage, endeavor, or engage in discussions with any employee or
              independent contractor of AngioDynamics for the purpose of (or with a view toward) having such employee or independent contractor leave the employment (or independent contractor assignment) of AngioDynamics for any reason, including leaving
              to render services to any Conflicting Organization.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">4.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Mutual Non-Disparagement</font>:&#160; Executive will not
              disparage any released party (as specified in <font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Exhibit A</u></font> to the Severance Agreement) (each, a &#8220;Released Party&#8221;) or otherwise take any action which could
              reasonably be expected to adversely affect the personal or professional reputation of any Released Party.&#160; AngioDynamics, Inc. (or its successor) or the ultimate parent company of AngioDynamics, Inc. (if AngioDynamics, Inc. is a subsidiary of
              another entity on Executive&#8217;s termination date) shall instruct the members of its Board of Directors and its executive officers to not disparage Executive or otherwise take any action which could reasonably be expected to adversely affect the
              personal or professional reputation of Executive. Notwithstanding the foregoing, in no </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
      </div>
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 26 of 30 pages</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div id="DSPFPageHeader">
        <div><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">event will any truthful, legally required disclosure or action be deemed to violate this Section, regardless of the content of such disclosure or the
              nature of such action.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">5.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">Miscellaneous.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">a.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">This Agreement is personal to Executive and may not be assigned by Executive. This Agreement shall inure to the benefit of AngioDynamics, its successors,
              and assigns.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">b.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Any dispute arising under or in connection with this Agreement or related to any matter which is the subject of this Agreement shall be subject to the
              exclusive jurisdiction of the state and federal courts located in New York, and this Agreement shall be construed under and according to the laws of the State of New York, without regard to its conflict of laws rules.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">c.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Executive acknowledges that any breach or threatened breach of this Agreement by Executive will cause AngioDynamics material and irreparable injury and
              monetary damages may not be an adequate remedy for such injury.&#160; In the event of a breach or threatened breach of this Agreement, AngioDynamics may pursue any remedies at law or equity available to it, including injunctive relief.&#160;
              Notwithstanding anything contained in this Agreement to the contrary, in addition to any remedies available to AngioDynamics (and not in exclusion of any such remedies) in the event of a breach of this Agreement, Executive shall be required
              to remit to AngioDynamics any severance payments paid to Executive by AngioDynamics pursuant to the Severance Agreement.</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 27 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="ze4695c3e1dfd42129083662a40830ab7">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">d.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">If any provision of this Agreement is held by any court of competent jurisdiction to be illegal, overly broad, invalid, or otherwise unenforceable in
              duration, geographical coverage, substantive scope, or otherwise, then this Agreement will be deemed amended to the extent necessary to render the otherwise unenforceable provision, and the rest of the Agreement, valid and enforceable.&#160; If a
              court declines to amend this Agreement as provided herein, the invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of the remaining provisions, which shall be enforced as if the
              offending provision had not been included in this Agreement.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">e.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">In the event of a violation of this Agreement, the time limitations set forth in this Agreement shall be extended for a period of time equal to the
              period of time during which such breach occurs, and, in the event AngioDynamics is required to seek relief from such breach before any court, board, or other tribunal, then the time limitation shall be extended for a period of time equal to
              the pendency of such proceedings, including all appeals.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">f.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">For twenty-four (24) months following the termination of Executive&#8217;s employment with AngioDynamics pursuant to the Severance Agreement, Executive agrees
              to show this Agreement to any prospective employer before Executive directly or indirectly owns, manages, operates, controls, becomes employed by, becomes a shareholder of, becomes a director of, becomes an officer of, participates in,
              contracts with, or becomes connected in any capacity or in any manner with such person or entity during any restrictive period provided in this Agreement.&#160; Executive also agrees to </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
      </div>
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 28 of 30 pages</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div id="DSPFPageHeader">
        <div><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">inform AngioDynamics at the time Executive gives notice of separation from employment, of the identity of Executive&#8217;s new employer and Executive&#8217;s new
              job title and responsibilities.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 97%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">g.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">EXECUTIVE ACKNOWLEDGES HAVING READ, EXECUTED, AND RECEIVED A COPY OF THIS AGREEMENT, UNDERSTANDS HIS/HER OBLIGATIONS UNDER THIS AGREEMENT, SIGNS IT
              VOLUNTARILY, INTENDS TO BE LEGALLY BOUND BY THIS AGREEMENT, AND AGREES THAT WITH RESPECT TO THE SUBJECT MATTER HEREOF IT IS EXECUTIVE&#8217;S ENTIRE AGREEMENT WITH ANGIODYNAMICS AND SUPERSEDES ANY PREVIOUS ORAL OR WRITTEN COMMUNICATIONS,
              REPRESENTATIONS, UNDERSTANDINGS, OR AGREEMENTS WITH ANGIODYNAMICS OR ANY OF ITS OFFICIALS OR REPRESENTATIVES.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    Executive further acknowledges that the restrictions imposed by this Agreement are necessary and reasonable to protect AngioDynamics&#8217; business interests and will not preclude Executive from becoming gainfully employed in a suitable capacity following
    the termination of Executive&#8217;s employment with AngioDynamics given Executive&#8217;s general knowledge and experience.</div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;">[Signature Page Follows]</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
    </div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 29 of 30 pages</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; margin-bottom: 36pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">IN WITNESS WHEREOF, Executive and AngioDynamics have hereunto affixed their signatures, this _____________ day of ______________________ 20
    ______.</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">___________________________________________</div>
  <div style="text-align: left; margin-bottom: 24pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Executive</div>
  <div style="text-align: left; margin-bottom: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">AngioDynamics, Inc.</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">___________________________________________</div>
  <div style="text-align: left; margin-bottom: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Signature</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">___________________________________________</div>
  <div style="text-align: left; margin-bottom: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Print Name</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">___________________________________________</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Title</div>
  <div><br>
  </div>
  <div style="margin-top: 12pt;"><br>
  </div>
  <div id="DSPFPageFooter">
    <div><br>
    </div>
  </div>
  <div style="text-align: center;"><font id="DSPFPageNumber" style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;">Page 30 of 30 pages</font>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>an55676910-ex10_2.htm
<DESCRIPTION>FORM OF AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Cadwalader, Wickersham & Taft LLP
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left; color: #000000;">
  <div id="DSPFPageHeader">
    <div style="text-align: right;"><font style="font-weight: bold; font-size: 12pt;">Exhibit 10.2</font><br>
    </div>
  </div>
  <div><br>
  </div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">THIS AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Agreement</u></font>&#8221;), is made effective as of January 29, 2021 between AngioDynamics, Inc., a Delaware corporation (the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Company</u></font>&#8221;),




    and [&#8226;], an individual resident of [&#8226;] (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Executive</u></font>&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">WHEREAS, the Company considers it essential to the best interests of its shareholders to foster the continued employment of
    key management personnel; and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">WHEREAS, the Board recognizes that, as is the case with many publicly held corporations, the possibility of a Change in
    Control exists and that such possibility, and the uncertainty and questions which it may raise among management, may result in the departure or distraction of management personnel to the detriment of the Company and its shareholders; and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">WHEREAS, the Board has determined that appropriate steps should be taken to reinforce and encourage the continued attention
    and dedication of members of the Company&#8217;s management, including the Executive, to their assigned duties without distraction in the face of potentially disturbing circumstances arising from the possibility of a Change in Control; and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">WHEREAS, the Company and the Executive previously entered into that certain Change in Control Agreement (as amended,
    modified, or supplemented from time to time, the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Original Agreement</u></font>&#8221;), and each of the Company and the Executive desire to amend and restate the Original Agreement
    in its entirety as set forth herein;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Company and the Executive
    hereby agree that the Original Agreement is hereby amended and restated in its entirety as follows:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">1.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Defined Terms</u></font>. The definitions of
    capitalized terms used in this Agreement are provided in the last Section hereof.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">2.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Term of Agreement</u></font>. The Term of
    this Agreement shall commence on the date hereof and shall continue in effect through December 31, 2021; provided, however, that effective January 1, 2022 and each January 1 thereafter, the Term that is then in effect shall automatically be extended
    for one additional year unless the Company has given at least sixty (60) days&#8217; written notice before the January 1 in question that the Term that is in effect at the time such notice is given will not be extended; and further provided, however, that if
    a Change in Control occurs during the Term, the Term shall expire no earlier than twenty-four (24) calendar months after the calendar month in which such Change in Control occurs. <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">Notwithstanding the foregoing, this Agreement shall terminate if the Executive ceases to be an employee of the Company and its subsidiaries for any reason prior to a Change in Control.</font><font style="font-size: 8pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">&#160; </font><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">However, anything in this Agreement (including the preceding sentence) to the
      contrary notwithstanding, i</font>f a Change in Control occurs and if,</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <!--PROfilePageNumberReset%Num%2%Page % of 29 pages%-->
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">within three (3) months prior to the date on which such Change in Control occurs, the Executive&#8217;s employment with the Company is terminated by
    the Company without Cause or an event occurs that would, if it took place after the Change in Control, constitute Good Reason for termination of employment by the Executive, and if it is reasonably demonstrated by the Executive that such termination of
    employment by the Company or event constituting Good Reason for termination of employment by the Executive (a) was undertaken at the request of a third party who has taken steps reasonably calculated to effect the Change in Control, or (b) otherwise
    arose in connection with or in anticipation of the Change in Control, then for purposes of this Agreement such termination of employment by the Company without Cause or event constituting Good Reason shall be deemed to occur during the twenty-four (24)
    month period following the Change in Control and, if the Executive terminates the Executive&#8217;s employment for such Good Reason before the Change in Control, such termination of employment by the Executive shall likewise be deemed to occur during the
    twenty-four (24) month period following the Change in Control (it being understood that, in each case, the Review Period (as defined below) shall be deemed to commence on the date of the applicable Change in Control).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">3.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Company&#8217;s Covenants Summarized</u></font>. In
    order to induce the Executive to remain in the employ of the Company and in consideration of the Executive&#8217;s covenants set forth in Section 4 hereof, the Company agrees, under the conditions described herein, to pay the Executive the Severance Payments
    and the other payments and benefits described herein. Except as provided in Section 2, Section 6.3, Section 9.1, or Section 14.2 hereof, no amounts shall be payable under this Agreement unless the Executive&#8217;s employment with the Company terminates
    following a Change in Control and during the Term. This Agreement shall not be construed as creating an express or implied contract of employment enforceable against the Company nor, except as provided in Section 4 below, enforceable against the
    Executive, and, except as otherwise agreed in writing between the Executive and the Company, the Executive shall not have any right to be retained in the employ of the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">4.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>The Executive&#8217;s Covenants</u></font>. The
    Executive agrees to remain in the employ of the Company, subject to the terms and conditions of this Agreement, if a Potential Change in Control occurs during the Term and the Executive is then in the employ of the Company, until the earliest of (a)
    the date which is six (6) months after the date of such Potential Change in Control, (b) the date of a Change in Control, (c) the date of termination by the Executive of the Executive&#8217;s employment for Good Reason or by reason of death, Disability, or
    Retirement, or (d) the termination by the Company of the Executive&#8217;s employment for any reason; provided that Executive&#8217;s agreement to remain in the employ of the Company shall be subject to the condition that no adverse change occurs after the
    Potential Change in Control in the Executive&#8217;s title, duties, responsibilities, authority, reporting relationships, compensation, benefits, or indemnification rights.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">5. <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Certain Compensation Other Than Severance
        Payments</u></font>.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">5.1&#160; If the Executive&#8217;s employment shall be terminated for any reason following a Change in Control and during the Term, the
    Company shall pay the Executive&#8217;s</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 2 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">full salary through the date of termination at the rate in effect immediately prior to the date of termination or, if higher, the rate in
    effect immediately prior to the first occurrence of an event or circumstance constituting Good Reason, together with all compensation and benefits payable to the Executive through the date of termination under the terms of the Company&#8217;s compensation
    and benefit plans, programs, and arrangements as in effect immediately prior to the date of termination or, if more favorable to the Executive, as in effect immediately prior to the first occurrence of an event or circumstance constituting Good Reason.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">5.2&#160; Subject to Section 6.1 hereof, if the Executive&#8217;s employment shall be terminated for any reason following a Change in
    Control and during the Term, the Company shall pay to the Executive the Executive&#8217;s normal post-termination compensation and benefits as such payments become due. Any such post-termination compensation and benefits shall be determined under, and paid
    in accordance with, the Company&#8217;s retirement, insurance and other compensation and benefit plans, programs, and arrangements as in effect immediately prior to the date of termination or, if more favorable to the Executive, as in effect immediately
    prior to the occurrence of the first event or circumstance constituting Good Reason.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">6.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Severance Payments</u></font>.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">6.1&#160; Subject to Section 6.2 and Section 6.3 hereof, if the Executive&#8217;s employment is terminated following a Change in Control
    and during the Term either by the Company or by the Executive, other than (a) by the Company for Cause, (b) by reason of death or Disability, or (c) by the Executive without Good Reason, (any such employment termination being hereafter sometimes
    referred to as a &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Compensable Termination</u></font>&#8221;), then the Company shall pay the Executive the amounts, and provide the Executive the benefits, described in this Section
    6.1 (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Severance Payments</u></font>&#8221;), in addition to any payments and benefits to which the Executive is entitled under Section 5 hereof. Notwithstanding the foregoing, the
    Executive shall not be eligible to receive any payment or benefit provided for in this Section 6.1 unless the Executive shall have executed a release substantially in the form of <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Exhibit




        A</u></font> hereto, and a covenant not to compete and other restrictions substantially in the form of <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Exhibit B</u></font> hereto, in each case within sixty (60) days
    following the date of the Compensable Termination (the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Review Period</u></font>&#8221;), and shall not have revoked said release.&#160; The Severance Payments are in lieu of any severance
    benefits that would otherwise be payable or provided pursuant to any severance plan or practice of the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(i)&#160; The Company shall pay the Executive, at the time provided in Section 6.2 below, the Executive&#8217;s
    annual bonus for the fiscal year of the Company preceding the fiscal year of the Company in which the Compensable Termination occurs, if unpaid at the time of the Compensable Termination, the amount of such bonus to be determined by the Compensation
    Committee of the Board on a basis no less favorable to the Executive than its bonus determinations with respect to the Executive prior to the Change in Control, unless the Committee made no bonus determinations with respect to the Executive before the
    Change in</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 3 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt;">Control, in which case on a basis no less favorable to the Executive than its bonus determinations with respect to other
    executives of comparable rank before the Change in Control.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(ii)&#160; The Company shall pay the Executive, at the time provided in Section 6.2 below, a prorated annual
    bonus for the fiscal year of the Company in which the Compensable Termination occurs, such prorated bonus to be determined by multiplying the &#8220;Applicable Average Bonus&#8221; as defined below in this subsection (ii) by a fraction, the numerator of which
    shall be the number of days elapsed in such fiscal year through (and including) the date on which the Compensable Termination occurs and the denominator of which shall be the number 365.&#160; For purposes of this Agreement, the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Applicable Average Bonus</u></font>&#8221; means the higher of (A) the average of all annual bonuses (including any deferred bonuses) awarded to the Executive during the thirty-six (36) months immediately
    preceding the Compensable Termination or, if the Executive was employed by the Company for less than thirty-six (36) months before the Compensable Termination, during the period of the Executive&#8217;s employment by the Company prior to the Compensable
    Termination (annualizing any bonus awarded for less than a full year of employment), or (B) the average of all annual bonuses (including any deferred bonuses) awarded to the Executive during the three (3) fiscal years of the Company that precede the
    fiscal year in which the Compensable Termination occurs or during the portion of such three fiscal years in which the Executive was employed by the Company (annualizing any bonus awarded for less than a full year of employment), or (C) the average of
    all annual bonuses (including any deferred bonuses) awarded to the Executive during the thirty-six (36) months preceding the date on which the Change in Control occurred or during the portion of such thirty-six (36) month period in which the Executive
    was employed by the Company (annualizing any bonus awarded for less than a full year of employment).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(iii)&#160; The Company shall pay the Executive, at the time provided in Section 6.2 below, a lump sum cash
    payment equal to one and one-half (1.5) times the sum of (x) the Executive&#8217;s annual base salary at the rate in effect immediately prior to the Compensable Termination or, if higher, in effect immediately prior to the first occurrence of an event or
    circumstance constituting Good Reason (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Base Salary</u></font>&#8221;), and (y) the Executive&#8217;s annual cash bonus target at the rate in effect immediately prior to the Compensable
    Termination or, if higher, in effect immediately prior to the first occurrence of an event or circumstance constituting Good Reason (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Target Bonus</u></font>&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(iv)&#160; The Company will pay the Executive for all earned but unused vacation leave at the time of the
    Compensable Termination.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(v)&#160; Subject to the Executive&#8217;s timely election and continued eligibility for continuation of coverage
    under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>COBRA</u></font>&#8221;), the Company shall continue the Executive&#8217;s participation in the Company&#8217;s
    group medical, dental, vision, and</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 4 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt;">prescription drug coverage at no cost to the Executive and the Executive&#8217;s dependents for a period of eighteen (18) months
    following the date of the Compensable Termination; provided, that, if such continuation is not permitted under the terms of the applicable Company benefit plan or program for all or any portion of such period, would result in the imposition of
    additional taxes or penalties (including, without limitation, under Section 105(h) of the Code), or would otherwise violate any applicable law, then the Company shall instead pay the Executive an additional cash amount per month during the period when
    such continuation would be so prohibited or subject to additional taxes or penalties equal to the total COBRA premium that would have been required to so continue the Executive&#8217;s (and the Executive&#8217;s dependents&#8217;) participation in such medical, dental,
    vision, and prescription drug programs.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(vi)&#160; Any stock options, restricted stock, restricted stock units, performance shares, performance share
    units, or other equity or equity-based awards granted to the Executive on or following the date of this Agreement, but prior to a Change in Control, shall vest in full, with any performance-based vesting requirements deemed achieved at the &#8220;target&#8221;
    level.&#160; For the avoidance of doubt, any equity or equity-based awards granted to the Executive prior to the date of this Agreement, or following the date of a Change in Control, shall be treated in accordance with their respective terms and conditions.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">6.2&#160; All payments and benefits
      to be made or provided pursuant to subsections (i) through (iv) of Section 6.1 above shall be made, and payments and benefits pursuant to subsection (v) shall commence, within thirty (30)&#160;calendar days after the date on which the release attached
      hereto as </font><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);"><u>Exhibit A</u></font><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);"> becomes fully
      effective and irrevocable in accordance with its terms; provided, that, if (x) such thirty (30) calendar day period, together with the Review Period, spans two (2) calendar years, such payments and benefits shall not be made or commence until the
      second (2</font><sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup><font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">) such calendar year, and (y) if, on the date of the Executive&#8217;s Separation from Service the
      Executive is a Specified Employee, and to the extent necessary to avoid the imposition of any additional taxes, interest, or penalties under Section 409A of the Code, such payments shall be made six months and one day after the date of the
      Compensable Termination (or, if earlier, the date of the Executive&#8217;s death), with any such payments that would have been made earlier absent this proviso made in a single lump sum on such date.</font>&#160; For purposes of the preceding sentence, a &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Specified Employee</u></font>&#8221; means a &#8220;specified employee&#8221; who is subject to the special rule set forth in subsection (a)(2)(B)(i) of Section 409A of the Code and the regulations
    thereunder (including, without limitation, Treasury Regulation section 1.409A-1(i)) with respect to such payments.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">6.3&#160; In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i)
    constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Excise Tax</u></font>&#8221;),




    then Executive&#8217;s benefits under this Agreement shall be either</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 5 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt; text-indent: 36pt;">(i) delivered in full, or</div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt; text-indent: 36pt;">(ii) delivered as to such lesser extent which would result in no portion of such benefits being subject to
    the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, and local income taxes and the Excise Tax, results in the receipt by Executive on an after-tax basis, of the greatest amount of benefits,
    notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.&#160; If a reduction in severance and other benefits constituting &#8220;parachute payments&#8221; is necessary so that benefits are delivered to a lesser extent,
    reduction will occur in the following order: reduction of cash payments, cancellation of equity awards granted within the twelve (12) month period prior to a &#8220;change in control&#8221; (as determined under Code Section 280G) that are deemed to have been
    granted contingent upon the change in control (as determined under Code Section 280G), cancellation of accelerated vesting of equity awards, reduction of employee benefits.</div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Unless the Company and the Executive otherwise agree in writing, any determination required under this Section shall be made in writing by the
    Company&#8217;s independent public accountants (the &#8220;<font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Accountants</u></font>&#8221;), whose determination shall be conclusive and binding upon Executive and the Company for all purposes.&#160;
    For purposes of making the calculations required by this Section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of
    Section 280G and 4999 of the Code.&#160; The Company and the Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section.&#160; The Company shall bear all
    costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section.</div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">7.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Payments During Dispute</u></font>. Any payments
    to which the Executive may be entitled under this Agreement, including, without limitation, under Sections 5 and 6 hereof, shall be made forthwith on the applicable date(s) for payment specified in this Agreement.&#160; If for any reason the amount of any
    payment due to the Executive cannot be finally determined on that date, such amount shall be estimated on a good faith basis by the Company and the estimated amount shall be paid no later than ten (10) days after such date.&#160; As soon as practicable
    thereafter, the final determination of the amount due shall be made and any adjustment requiring a payment to or from the Executive shall be made as promptly as practicable.</div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">8.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Mitigation</u></font>. The Company agrees
    that, if the Executive&#8217;s employment with the Company terminates during the Term, the Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable or benefits to be provided to the Executive by the Company
    pursuant to Section 6 hereof or any other provision of this Agreement. Further, the amount of any payment or benefit provided for in this Agreement shall not be reduced (a) by any compensation earned by the Executive as the result of employment by
    another employer, (b) by retirement benefits, (c)</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 6 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">by offset against any amount claimed to be owed by the Executive to the Company, or (d) otherwise.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">9.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Successors; Binding Agreement</u></font>.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">9.1&#160; In addition to any obligations imposed by law upon any successor to the Company, the Company will require any successor
    (whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to perform the Company&#8217;s obligations under this Agreement in the same
    manner and to the same extent that the Company would be required to perform if no such succession had taken place. Failure of the Company to obtain such assumption and agreement prior to the effectiveness of any such succession during the Term shall be
    a breach of this Agreement and shall entitle the Executive to compensation from the Company in the same amount and on the same terms as the Executive would be entitled to hereunder if the Executive were to terminate the Executive&#8217;s employment for Good
    Reason after a Change in Control and during the Term, except that, for purposes of implementing the foregoing, the date on which any such succession becomes effective during the Term shall be deemed the date of the Compensable Termination.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">9.2&#160; This Agreement shall inure to the benefit of and be enforceable by the Executive&#8217;s personal or legal representatives,
    executors, administrators, successors, heirs, distributees, devisees, and legatees. If the Executive shall die while any amount would still be payable to the Executive hereunder (other than amounts which, by their terms, terminate upon the death of the
    Executive) if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives, or administrators of the Executive&#8217;s estate.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">10.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Notices</u></font>. For the purpose of this
    Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail, return receipt requested, postage prepaid,
    addressed, if to the Executive, to the Executive&#8217;s most recent address shown on the books and records of the Company at the time notice is given and, if to the Company, to the address set forth below, or to such other address as either party may have
    furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon actual receipt:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">To the Company:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">AngioDynamics, Inc.</div>
  <div style="text-align: justify; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">14 Plaza Drive</div>
  <div style="text-align: justify; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">Latham, NY 12110</div>
  <div style="text-align: justify; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 72pt;">Attention: Office of the General Counsel</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 7 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">11.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Miscellaneous</u></font>. No provision of
    this Agreement may be modified, waived, or discharged unless such waiver, modification, or discharge is agreed to in writing and signed by the Executive and such officer as may be specifically designated by the Board. No waiver by either party hereto
    at any time of any breach by the other party hereto of, or of any lack of compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at
    the same or at any prior or subsequent time. <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif; color: rgb(0, 0, 0);">This Agreement constitutes the entire agreement of the parties concerning the specific subject matter addressed
      by this Agreement and supersedes all prior agreements addressing the terms and conditions contained herein (including, without limitation, the Original Agreement).&#160; </font>The validity, interpretation, construction, and performance of this Agreement
    shall be governed by the laws of the State of New York. All references to sections of the Code or the Exchange Act shall be deemed also to refer to any successor provisions to such sections and to IRS or SEC regulations and official guidance published
    thereunder. Any payments provided for hereunder shall be subject to any applicable withholding required under federal, state, or local law and any additional withholding to which the Executive has agreed. The obligations of the Company and the
    Executive under this Agreement which by their nature may require either partial or total performance after the expiration of the Term (including, without limitation, those under Sections 6 and 7 hereof) shall survive such expiration.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">12.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Validity</u></font>. The invalidity or
    unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">13.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Counterparts</u></font>. This Agreement may
    be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.</div>
  <div style="text-align: left; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Settlement of Disputes; Arbitration</u></font>.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.1&#160; All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board and
    shall be in writing. Any denial by the Board of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon.
    The Board shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim and shall further allow the Executive to appeal to the Board a decision of the Board within sixty (60) days after notification by the Board
    that the Executive&#8217;s claim has been denied.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.2&#160; Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by
    arbitration in the Albany, New York metropolitan area in accordance with the employment dispute resolution rules of the American Arbitration Association then in effect. The arbitrator shall have the authority to require that the Company reimburse the
    Executive for the payment of all or any portion of the legal fees and expenses incurred by the Executive in connection with such dispute or</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 8 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">controversy. Judgment may be entered on the arbitrator&#8217;s award in any court having jurisdiction.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.3&#160; The Company agrees to use commercially reasonable efforts to administer this Agreement, and operate any deferred
    compensation plans in which the Executive participates from time to time that are aggregated with this Agreement or with any payment or benefit provided by this Agreement for purposes of Section 409A of the Code (e.g., account balance plans, nonaccount
    balance plans, separation pay plans, and plans that are neither account balance nor nonaccount balance plans), in good faith compliance with Code Section 409A to the extent necessary to avoid inclusion of any amounts of benefits payable hereunder in
    the Executive&#8217;s income pursuant to Section 409A(a)(1)(A) of the Code or the imposition of any additional taxes, interest, or penalties under Section 409A of the Code.&#160; Notwithstanding the foregoing, the Executive shall be solely liable for any
    additional taxes, interest, or penalties imposed under Section 409A of the Code, and the Company shall not be required to indemnify the Executive for any such amounts.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">15.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Definitions</u></font>. For purposes of this
    Agreement, the following terms shall have the meanings indicated below:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(A)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Affiliate</u></font>&#8221; shall have the meaning
    set forth in Rule 12b-2 promulgated under Section 12 of the Exchange Act.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(B)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Applicable Average Bonus</u></font>&#8221; shall
    have the meaning set forth in subsection (ii) of Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(C)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Base Salary</u></font>&#8221; shall have the
    meaning set forth in subsection (iii) of Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(D)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Beneficial Owner</u></font>&#8221; shall have the
    meaning set forth in Rule 13d-3 under the Exchange Act.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(E)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Board</u></font>&#8221; shall mean the Board of
    Directors of the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(F)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Cause</u></font>&#8221; for termination by the
    Company of the Executive&#8217;s employment shall mean (i) the willful and continued failure by the Executive to substantially perform the Executive&#8217;s duties with the Company as such duties were in effect prior to any change therein constituting Good Reason
    (other than any such failure resulting from the Executive&#8217;s incapacity due to physical or mental illness or any such failure after the occurrence of an event constituting Good Reason for resignation by the Executive) after a written demand for
    substantial performance is delivered to the Executive by the Board, which demand specifically identifies the manner in which the Board believes that the Executive has not substantially performed the Executive&#8217;s duties, provided that such failure will
    constitute Cause only if it remains uncured for more than thirty (30) days following receipt by the Executive of such written demand from the Board; (ii) the engaging by the Executive in willful conduct which is demonstrably and materially injurious to
    the</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 9 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Company or its subsidiaries, monetarily or otherwise, provided that such conduct will constitute Cause only if it remains uncured for more
    than thirty (30) days following receipt by the Executive of a written demand from the Board to cease such conduct; or (iii) the Executive&#8217;s conviction of (a) a felony or (b) a crime involving fraud, dishonesty, or moral turpitude. For purposes of
    clauses (i) and (ii) of this definition, no act, or failure to act, on the Executive&#8217;s part shall be deemed &#8220;willful&#8221; unless done, or omitted to be done, by the Executive not in good faith and without reasonable belief that the Executive&#8217;s act, or
    failure to act, was in the best interest of the Company.&#160; The Company shall notify the Executive in writing of any employment termination purporting to be for Cause on or before the date of such termination, which writing shall describe with
    specificity the conduct alleged to constitute Cause for such termination.&#160; Any purported termination of employment by the Company for Cause which does not satisfy the applicable requirements of this Section 15(F) shall be conclusively deemed to be a
    termination of employment by the Company without Cause for purposes of this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(G)&#160; A &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Change in Control</u></font>&#8221; shall mean
    that any of the following events has occurred:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(i)&#160; any Person is or becomes the Beneficial Owner, directly or&#160; &#160;&#160; indirectly, of securities of the
    Company representing more than fifty percent (50%) of the combined voting power of the Company&#8217;s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (A) of paragraph
    (iii) below; or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(ii)&#160; the following individuals cease for any reason to constitute a&#160; majority of the number of directors
    serving on the Board: individuals who, at the beginning of any period of two (2) consecutive years or less (not including any period prior to the date of this Agreement), constitute the Board and any new director (other than a director whose initial
    assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for
    election by the Company&#8217;s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of such period or whose appointment, election, or nomination for
    election was previously so approved or recommended; or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt; margin-left: 36pt;">(iii)&#160; there is consummated a merger or consolidation of the Company or any Subsidiary with any other
    corporation, other than (A) a merger or consolidation which would result in the voting securities of the Company&#160; &#160;&#160; outstanding immediately prior to such merger or consolidation continuing to&#160; &#160;&#160; represent (either by remaining outstanding or by being
    converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, at least sixty
    percent (60%) of the combined voting power of the securities of the Company or such surviving entity</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 10 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt;">or any parent thereof outstanding immediately after such merger or consolidation, or (B) a merger or consolidation effected
    to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power
    of the Company&#8217;s then outstanding securities; or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iv)&#160;&#160; the shareholders of the Company approve a plan of complete liquidation or dissolution of the
    Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets, other than a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets to an
    entity, at least sixty percent (60%) of the combined voting power of the voting securities of which are owned by shareholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(H)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>COBRA</u></font>&#8221; shall have the meaning set
    forth in subsection (v) of Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(I)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Code</u></font>&#8221; shall mean the Internal
    Revenue Code of 1986, as amended from time to time.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(J)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Company</u></font>&#8221; shall mean
    AngioDynamics, Inc. and, except in determining under Section 15(G) hereof whether or not any Change in Control of the Company has occurred, shall include any successor to its business and/or assets which assumes and agrees to perform this Agreement by
    operation of law, or otherwise.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(K)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Compensable Termination</u></font>&#8221; shall
    have the meaning set forth in Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(L)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Disability</u></font>&#8221; shall be deemed the
    reason for the termination by the Company of the Executive&#8217;s employment, if, as a result of the Executive&#8217;s incapacity due to physical or mental illness, the Executive shall have been absent from the full-time performance of the Executive&#8217;s duties with
    the Company for a period of six (6) consecutive months or for six (6) non-consecutive months within any period of twelve (12) consecutive months.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(M)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Exchange Act</u></font>&#8221; shall mean the
    Securities Exchange Act of 1934, as amended from time to time.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(N)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Executive</u></font>&#8221; shall mean the
    individual named in the first paragraph of this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(O)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Good Reason</u></font>&#8221; for termination by
    the Executive of the Executive&#8217;s employment shall mean the occurrence (without the Executive&#8217;s express written consent) after any Change in Control, of any one of the following acts by the Company, or failures</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 11 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">by the Company to act, unless, in the case of any act or failure to act described in paragraph (i), (iii), (iv), or (vi) below, such act or
    failure to act is corrected within thirty (30) calendar days after the Company&#8217;s receipt of written notice thereof given by the Executive within thirty (30) calendar days of such act or failure to act:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(i)&#160; the assignment to the Executive of any duties inconsistent with the Executive&#8217;s status or position in
    the Company immediately prior to the Change in Control, or a substantial adverse alteration in the nature, status, or scope of the Executive&#8217;s responsibilities or authority from the Executive&#8217;s responsibilities or authority immediately prior to the
    Change in Control, or a reduction in the Executive&#8217;s title;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(ii)&#160; a reduction by the Company in the Executive&#8217;s Base Salary or Target Bonus, in each case as in effect
    on the date of this Agreement or as they may be increased from time to time;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iii)&#160; a significant reduction in compensation, benefits, or reimbursements provided under any employment,
    compensation, employee benefit, or reimbursement plan or program in which the Executive is a participant which is not replaced with substantially equivalent compensation, benefits, or reimbursements under another plan, program, or arrangement at
    substantially the same cost (if any) to the Executive;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iv)&#160; the Company fails to pay or provide any amount or benefit that the Company is obligated to pay or
    provide under this Agreement or any other employment, compensation, benefit, or reimbursement plan, agreement, or arrangement of the Company to which the Executive is a party or in which the Executive participates;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(v)&#160; the relocation of the Executive&#8217;s principal place of employment to a location which increases the
    Executive&#8217;s one-way commuting distance by more than forty (40) miles, or the Company&#8217;s requiring the Executive to travel on business other than to an extent substantially consistent with the Executive&#8217;s business travel obligations prior to the Change
    in Control;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(vi)&#160; a significant adverse change occurs, whether of a quantitative or qualitative nature, in the
    indemnification protection provided to the Executive for acts and omissions arising out of the Executive&#8217;s service on behalf of the Company or any other entity at the request of the Company; or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(vii)&#160; the Company fails to obtain the assumption of this Agreement pursuant to Section&#160;9.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">The Executive&#8217;s right to terminate the Executive&#8217;s employment for Good Reason shall not be affected by the Executive&#8217;s incapacity due to
    physical or mental illness. The Executive&#8217;s continued employment shall not constitute consent to, or a waiver of rights with respect to,</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 12 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">any act or failure to act constituting Good Reason hereunder.&#160; To constitute Good Reason, the Executive must terminate the Executive&#8217;s
    employment with the Company within thirty (30) calendar days following the date that such event giving rise to Good Reason occurs (or, if later, the date of expiration of any applicable period that the Company has to cure such event).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(P)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Person</u></font>&#8221; shall have the meaning
    given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its Subsidiaries, (ii) a trustee or other fiduciary holding securities under an
    employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the shareholders of the Company in
    substantially the same proportions as their ownership of stock of the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(Q)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Potential Change in Control</u></font>&#8221;
    shall be deemed to have occurred if the event set forth in any one of the following paragraphs shall have occurred:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(i)&#160; the Company enters into an agreement, the consummation of which would result in the occurrence of a
    Change in Control;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(ii)&#160; the Company or any Person publicly announces an intention to take or to consider taking actions
    which, if consummated, would constitute a Change in Control;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iii)&#160; any Person becomes the Beneficial Owner, directly or indirectly, of securities of the Company
    representing fifteen percent (15%) or more of either the then outstanding shares of common stock of the Company or the combined voting power of the Company&#8217;s then outstanding securities (not including in the securities beneficially owned by such Person
    any securities acquired directly from the Company or its Affiliates); or</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; margin-left: 36pt; text-indent: 36pt;">(iv&#160;&#160; the Board adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change
    in Control has occurred.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(R)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Retirement</u></font>&#8221; shall be deemed the
    reason for the termination by the Executive of the Executive&#8217;s employment if such employment is terminated in accordance with the Company&#8217;s retirement policy (if any), including early retirement, generally applicable to its salaried employees.</div>
  <div style="text-align: justify; margin-top: 12pt; color: rgb(0, 0, 0); font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(S)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Review Period</u></font>&#8221;
    shall have the meaning set forth in Section 6.1 hereof.</div>
  <div style="text-align: justify; margin-top: 12pt; color: rgb(0, 0, 0); font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(T)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Separation from Service</u></font>&#8221;
    means termination of employment with the Company. However, the Executive shall not be deemed to have a Separation from</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 13 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Service unless such Separation from Service also constitutes a &#8220;separation from service&#8221; under Section 409A and the
    regulations promulgated thereunder.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(U)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Severance Payments</u></font>&#8221; shall have
    the meaning set forth in Section 6.1 hereof.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(V)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Subsidiary</u></font>&#8221; means a corporation
    or other form of business association of which shares (or other ownership interests) having more than fifty percent (50%) of the voting power are owned or controlled, directly or indirectly, by the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(W)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Target Bonus</u></font>&#8221; shall have the
    meaning set forth in subsection (iii) of Section 6.1.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(X)&#160; &#8220;<font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Term</u></font>&#8221; shall mean the period of
    time described in Section 2 hereof (including any extension or continuation described therein).</div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;">[Remainder of page intentionally left blank. Signature page follows.]</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 14 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date and year first above written.</div>
  <div style="text-align: justify; margin-top: 12pt;"><br>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">ANGIODYNAMICS, INC.</div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">By: _____________________</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Name: Stephen A. Trowbridge</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Title:&#160;&#160; EVP and CFO</div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">________________________</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">[&#8226;]</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 15 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-variant: small-caps; font-weight: bold;"><u>Exhibit A</u></div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">ANGIODYNAMICS, INC.</div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;"><u>RELEASE OF CLAIMS</u></div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">This Release of Claims (&#8220;Agreement&#8221;) is made by and between AngioDynamics, Inc. (the &#8220;Company&#8221;), and&#160; <font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>&#160;&#160; </u></font> (&#8220;Executive&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">WHEREAS, Executive has agreed to enter into a release of claims in favor of the Company upon certain events specified in the Amended and
    Restated Change in Control Agreement by and between Company and Executive, as amended (the &#8220;Severance Agreement&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">NOW THEREFORE, in consideration of the mutual promises made herein, Executive hereby agrees as follows:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">1.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Termination</u></font>. Executive&#8217;s
    employment from the Company terminated on [DATE].</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">2.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Confidential Information</u></font>.
    Executive shall continue to maintain the confidentiality of all confidential and proprietary information of the Company and shall continue to comply with the terms and conditions of the Proprietary Information and Nondisclosure Agreement between
    Executive and the Company (the &#8220;Confidentiality Agreement&#8221;), as well as <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Exhibit B</u></font> to the Severance Agreement. Executive shall return all the Company property and
    confidential and proprietary information in Executive&#8217;s possession to the Company on the Effective Date of this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">3.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Payment of Salary</u></font>. Executive
    acknowledges and represents that the Company has paid all salary, wages, bonuses, accrued vacation, commissions, and any and all other benefits due to Executive.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">4.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Release of Claims</u></font>. Except as set
    forth in the last paragraph of this Section 4, Executive agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company.&#160; Executive, on behalf of himself or herself, and Executive&#8217;s
    respective heirs, family members, executors, and assigns, hereby fully and forever releases the Company and its past, present, and future officers, agents, directors, employees, investors, shareholders, administrators, affiliates, divisions,
    subsidiaries, parents, predecessor and successor corporations, and assigns, from, and agrees not to sue or otherwise institute or cause to be instituted any legal or administrative proceedings concerning any claim, duty, obligation, or cause of action
    relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive may possess arising from any omissions, acts, or facts that have occurred up until and including the Effective Date of this Agreement
    including, without limitation:</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 16 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(a) any and all claims relating to or arising from Executive&#8217;s employment relationship with the Company and the termination
    of that relationship;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(b) any and all claims relating to, or arising from, Executive&#8217;s right to purchase, or actual purchase of shares of stock of
    the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(c) any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination;
    breach of contract, both express and implied; breach of a covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation;
    negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; and conversion;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(d) any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of
    the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974, and The Worker
    Adjustment and Retraining Notification Act;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(e) any and all claims for violation of the federal, or any state, constitution;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">(g) any and all claims for attorneys&#8217; fees and costs.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Executive agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to
    the matters released.&#160; Nothing in this Agreement waives Executive&#8217;s rights to indemnification or any payments under any fiduciary insurance policy, if any, provided by any act or agreement of the Company, state or federal law or policy of insurance, or
    to the Severance Payments (as defined in the Severance Agreement).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">5.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Acknowledgment of Waiver of Claims under ADEA</u></font>.
    Executive acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;ADEA&#8221;) and that this waiver and release is knowing and voluntary. Executive and the Company agree that
    this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement.&#160; Executive acknowledges that the consideration given for this waiver and release Agreement is in addition to
    anything of value to which Executive was already entitled.&#160; Executive further acknowledges that Executive has been advised by this writing that (a) Executive should consult with an attorney prior to executing this Agreement; (b) Executive has at least
    [twenty-one (21)][forty-five (45)] days within which to consider this Agreement; (c) Executive has seven (7) days following the execution</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 17 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">of this Agreement to revoke the Agreement; (d) this Agreement shall not be effective until the revocation period has expired (provided
    Executive has not revoked this Agreement); and (e) nothing in this Agreement prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition
    precedent, penalties or costs for doing so, unless specifically authorized by federal law. Any revocation should be in writing and delivered to [HR Contact Name] at the Company by close of business on the seventh (7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day from the date that
    Executive signs this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">6.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Pending or Future Lawsuits</u></font>.
    Executive represents that Executive has no lawsuits, claims, or actions pending in Executive&#8217;s name, or on behalf of any other person or entity, against the Company or any other person or entity referred to herein. Executive also represents that
    Executive does not intend to bring any claims on Executive&#8217;s own behalf or on behalf of any other person or entity against the Company or any other person or entity referred to herein.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">7.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Application for Employment</u></font>.
    Executive understands and agrees that, as a condition of this Agreement, Executive shall not be entitled to any employment with the Company, its subsidiaries, or any successor, and Executive hereby waives any right, or alleged right, of employment or
    re-employment with the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">8.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Cooperation</u></font>. Executive agrees
    that Executive will not counsel or assist any attorneys or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against the Company and/or any officer, director,
    employee, agent, representative, shareholder, or attorney of the Company, unless under a subpoena or other court order to do so.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">9.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Cooperation with Company</u></font>.
    Executive agrees to cooperate, at the request of the Company, in the defense and/or prosecution of any charges, claims, investigations (internal or external), administrative proceedings, and/or lawsuits relating to matters occurring during or relating
    to Executive&#8217;s period of employment about which Executive may have relevant information. Executive shall further reasonably cooperate with regard to the transition of Executive&#8217;s job duties and business relationships. Executive agrees to respond to
    reasonable requests for information from the Company in a timely manner.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">10.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Admission of Liability</u></font>. No
    action taken by the Company, either previously or in connection with this Agreement shall be deemed or construed to be (a) an admission of the truth or falsity of any claims heretofore made or (b) an acknowledgment or admission by the Company of any
    fault or liability whatsoever to Executive or to any third party.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">11.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Costs</u></font>. Executive shall bear
    Executive&#8217;s own costs, expert fees, attorneys&#8217; fees, and other fees incurred in connection with executing this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">12.&#160;&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Authority</u></font>. Executive represents
    and warrants that Executive has the capacity to act on Executive&#8217;s own behalf and on behalf of all who might claim through Executive to bind them to the terms and conditions of this Agreement.</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 18 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">13.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Representations</u></font>. Executive
    represents that Executive has had the opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the provisions of this Agreement.&#160; Executive has not relied upon any representations or statements made by the
    Company which are not specifically set forth in this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">14.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Severability</u></font>. In the event that
    any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">15.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Entire Agreement</u></font>. This Agreement,
    along with the Confidentiality Agreement, the Severance Agreement, and Executive&#8217;s written equity compensation agreements with the Company, represents the entire agreement and understanding between the Company and Executive concerning Executive&#8217;s
    separation from the Company.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">16.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>No Oral Modification</u></font>. This
    Agreement may only be amended in writing signed by Executive and a duly authorized officer of the Company (other than Executive).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">17.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Governing Law</u></font>. This Agreement
    shall be governed by the internal substantive laws, but not the choice of law rules, of the State of New York.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">18. <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Effective Date</u></font>. Executive has
    seven (7) days after Executive signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Executive signed this Agreement (&#8220;Effective Date&#8221;), provided that Executive has not timely revoked this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 36pt;">19.&#160; <font style="font-size: 12pt; font-family: Arial,Helvetica,sans-serif;"><u>Voluntary Execution of Agreement</u></font>.
    This Agreement is executed voluntarily and without any duress or undue influence on the part of Executive, with the full intent of releasing all claims. Executive acknowledges that:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(a) Executive has read this Agreement;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(b) Executive had the opportunity of being represented in the preparation, negotiation, and execution of this Agreement by
    legal counsel of Executive&#8217;s own choice or Executive has voluntarily declined to seek such counsel;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(c) Executive understands the terms and consequences of this Agreement and of the releases it contains;</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt; text-indent: 72pt;">(d) Executive is fully aware of the legal and binding effect of this Agreement.</div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">[Remainder of page intentionally left blank. Signature page follows.]</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 19 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">IN WITNESS WHEREOF, Executive has have executed this Agreement on the date set forth below.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"> <br>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Dated:&#160; [MONTH], 20___</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">By:&#160;&#160;&#160;&#160;&#160; ____________________________<br>
  </div>
  <div style="text-align: left; text-indent: 36pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">[Executive]</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 20 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-variant: small-caps; font-weight: bold;"><u>Exhibit B</u></div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">ANGIODYNAMICS, INC.</div>
  <div style="text-align: center; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;"><u>NON-COMPETITION AND NON-SOLICITATION AGREEMENT</u></div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">This Non-Competition and Non-Solicitation Agreement (&#8220;Agreement&#8221;) is made by and between AngioDynamics, Inc. (the &#8220;Company&#8221;), and&#160; <font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>&#160;&#160; </u></font> (&#8220;Executive&#8221;).</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">WHEREAS, Executive has agreed to enter into a non-competition and non-solicitation agreement in favor of the Company upon certain events
    specified in the Amended and Restated Change in Control Agreement by and between the Company and Executive, as amended (the &#8220;Severance Agreement&#8221;); and</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">WHEREAS, in consideration for the Company&#8217;s promises and covenants contained in the Severance Agreement, Executive agrees to be bound by the
    terms of this Agreement.</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">NOW THEREFORE, in consideration of the mutual promises made herein and in the Severance Agreement, Executive and the Company hereby agree as
    follows:</div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">
    <table cellspacing="0" cellpadding="0" border="0" id="zfc653d5374a34ad595d39e3fc2db0ade" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">1.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Terms used in this Agreement</font>:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">a.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>AngioDynamics</u></font> means AngioDynamics, Inc., its successors or
              assigns, and any of their existing and future divisions, subsidiaries, and affiliates.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">b.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Confidential Information</u></font> means all trade secrets, proprietary
              information, know-how, and confidential information disclosed to Executive or known by Executive as a result of Executive&#8217;s employment by AngioDynamics, not generally known in the trade or industry in which AngioDynamics is engaged, about
              AngioDynamics&#8217; business operations, customers, suppliers, products, processes, machines, systems, and services, including research, development, manufacturing, purchasing, finance, data processing, engineering, marketing, designs, concepts,
              know-how, merchandising, and selling, and corresponding information about the products, processes, machines, and services of AngioDynamics, acquired by Executive during Executive&#8217;s employment by AngioDynamics. The fact that information is not
              patentable or </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
        <div><br>
        </div>
      </div>
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 21 of 29 pages</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div id="DSPFPageHeader">
        <div><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">copyrightable shall not affect its status as Confidential Information.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">c.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Conflicting Product</u></font> means any product, process, machine, or
              service of any person or organization other than AngioDynamics, whether now existing or hereafter developed: (a) which is identical to, substantially the same as, an adequate substitute for, resembles, or competes with a product, process,
              machine, system, or service upon or with which Executive worked during Executive&#8217;s term of employment with AngioDynamics or about which Executive acquired Confidential Information; or (b) whose use or marketability could be enhanced by
              application to it of Confidential Information to which Executive had access during Executive&#8217;s employment with</div>
          </td>
        </tr>

    </table>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 22 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;">
    <table cellspacing="0" cellpadding="0" border="0" id="z601adf9135da4c348ed9fac96ea23d72" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">AngioDynamics; or (c) which is (or could reasonably be anticipated to be) marketed or distributed in such a manner and in such a geographic area as to
              actually compete with such a product, process, machine, or service of AngioDynamics.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">d.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Conflicting Organization</u></font> means any person or organization,
              which is now or hereafter engaged directly or indirectly in research on or the acquisition, development, production, distribution, marketing, providing, or selling of a Conflicting Product.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">e.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Terms not defined herein shall have the meaning ascribed to such terms in the Severance Agreement.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">2.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Non-Competition</font>.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">a.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">For a period of twenty four (24) months after termination of Executive&#8217;s employment with AngioDynamics pursuant to the Severance Agreement, Executive
              will not render services, directly or indirectly, to any Conflicting Organization.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">However, notwithstanding the foregoing, Executive understands that he/she may work for a Conflicting Organization whose business is diversified,
              provided Executive&#8217;s work for the Conflicting Organization does not involve selling, managing, overseeing, developing, creating, promoting, servicing, involvement in the financing and/or accounting of, or other responsibility for any
              Conflicting Product on which Executive worked or gained Confidential Information during the last two (2) years of Executive&#8217;s employment with AngioDynamics. Prior to accepting such employment, the Conflicting Organization and Executive must
              provide written assurances reasonably satisfactory to </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
        <div><br>
        </div>
      </div>
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 23 of 29 pages</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div id="DSPFPageHeader">
        <div><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">AngioDynamics (as determined in good faith), that Executive will not render services, directly or indirectly, in connection with any Conflicting
              Product on which Executive worked or gained Confidential Information during the last two (2) years of Executive&#8217;s employment with AngioDynamics and that necessary safeguards have been put in place to ensure that this does not happen.&#160; This
              section shall be construed in a manner to give effect to the restrictions contained herein to the maximum extent permitted by applicable law.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">b.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">The restrictions set forth in Section 2(a) apply in the United States and in any foreign country or foreign territory where AngioDynamics produces,
              sells, or markets its goods and services.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">3.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Non-Solicitation</font>.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">a.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Business Relations</font>. Executive agrees that for a
              period of twenty four (24) months after the termination of Executive&#8217;s employment with AngioDynamics pursuant to the Severance Agreement, Executive will not solicit, induce, attempt to induce, appropriate, direct, or assist another to
              appropriate or direct, or provide any services to any current customer, supplier, licensee, or other business relation (defined as any customer, supplier, licensee, or other business relation of AngioDynamics with whom Executive had dealings
              and/or for whom Executive performed services at any time</div>
          </td>
        </tr>

    </table>
  </div>
  <br>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 24 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;">
    <table cellspacing="0" cellpadding="0" border="0" id="z80e2494a326c40cbba4d00dc6e5f9ba7" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">during the last two (2) years of Executive&#8217;s employment with AngioDynamics) to cease doing business with AngioDynamics (including, without limitation,
              making any negative statements or communications concerning AngioDynamics or any of its directors, officers, or employees).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">b.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Employees</font>. Executive agrees that for a period of
              twenty four (24) months after the termination of Executive&#8217;s employment with AngioDynamics pursuant to the Severance Agreement, Executive will not solicit, interfere with, encourage, endeavor, or engage in discussions with any employee or
              independent contractor of AngioDynamics for the purpose of (or with a view toward) having such employee or independent contractor leave the employment (or independent contractor assignment) of AngioDynamics for any reason, including leaving
              to render services to any Conflicting Organization.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">4.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif; font-weight: bold;">Mutual Non-Disparagement</font>:&#160; Executive will not
              disparage any released party (as specified in <font style="font-size: 12pt; font-family: Arial, Helvetica, sans-serif;"><u>Exhibit A</u></font> to the Severance Agreement) (each, a &#8220;Released Party&#8221;) or otherwise take any action which could
              reasonably be expected to adversely affect the personal or professional reputation of any Released Party.&#160; AngioDynamics, Inc. (or its successor) or the ultimate parent company of AngioDynamics, Inc. (if AngioDynamics, Inc. is a subsidiary of
              another entity on Executive&#8217;s termination date) shall instruct the members of its Board of Directors and its executive officers to not disparage Executive or otherwise take any action which could reasonably be expected to adversely affect the
              personal or professional reputation of Executive. Notwithstanding the foregoing, in no event will any truthful, legally required disclosure or action be deemed to violate this Section, regardless of the </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
        <div><br>
        </div>
      </div>
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 25 of 29 pages</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div id="DSPFPageHeader">
        <div><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">content of such disclosure or the nature of such action.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">5.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt; font-weight: bold;">Miscellaneous.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">a.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">This Agreement is personal to Executive and may not be assigned by Executive. This Agreement shall inure to the benefit of AngioDynamics, its
              successors, and assigns.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">b.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Any dispute arising under or in connection with this Agreement or related to any matter which is the subject of this Agreement shall be subject to the
              exclusive jurisdiction of the state and federal courts located in New York, and this Agreement shall be construed under and according to the laws of the State of New York, without regard to its conflict of laws rules.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">c.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Executive acknowledges that any breach or threatened breach of this Agreement by Executive will cause AngioDynamics material and irreparable injury
              and monetary damages may not be an adequate remedy for such injury.&#160; In the event of a breach or threatened breach of this Agreement, AngioDynamics may pursue any remedies at law or equity available to it, including injunctive relief.&#160;
              Notwithstanding anything contained in this Agreement to the contrary, in addition to any remedies available to AngioDynamics (and not in exclusion of any such remedies) in the event of a breach of this Agreement, Executive shall be required
              to remit to AngioDynamics any</div>
          </td>
        </tr>

    </table>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 26 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial,Helvetica,sans-serif; font-size: 12pt;">
    <table cellspacing="0" cellpadding="0" border="0" id="z49d892177be0443d91207ceb56f012b0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">severance payments paid to Executive by AngioDynamics pursuant to the Severance Agreement.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">d.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">If any provision of this Agreement is held by any court of competent jurisdiction to be illegal, overly broad, invalid, or otherwise unenforceable in
              duration, geographical coverage, substantive scope, or otherwise, then this Agreement will be deemed amended to the extent necessary to render the otherwise unenforceable provision, and the rest of the Agreement, valid and enforceable.&#160; If a
              court declines to amend this Agreement as provided herein, the invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of the remaining provisions, which shall be enforced as if the
              offending provision had not been included in this Agreement.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">e.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">In the event of a violation of this Agreement, the time limitations set forth in this Agreement shall be extended for a period of time equal to the
              period of time during which such breach occurs, and, in the event AngioDynamics is required to seek relief from such breach before any court, board, or other tribunal, then the time limitation shall be extended for a period of time equal to
              the pendency of such proceedings, including all appeals.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">f.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">For twenty-four (24) months following the termination of Executive&#8217;s employment with AngioDynamics pursuant to the Severance Agreement, Executive
              agrees to show this Agreement to any prospective employer before Executive directly or indirectly owns, manages, operates, controls, becomes employed by, becomes a shareholder of, becomes a director of, becomes an officer of, participates in,
              contracts with, or becomes connected in any capacity or in any manner with </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageFooter">
        <div><br>
        </div>
        <div><br>
        </div>
      </div>
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 27 of 29 pages</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div id="DSPFPageHeader">
        <div><br>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">such person or entity during any restrictive period provided in this Agreement.&#160; Executive also agrees to inform AngioDynamics at the time Executive
              gives notice of separation from employment, of the identity of Executive&#8217;s new employer and Executive&#8217;s new job title and responsibilities.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">g.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">EXECUTIVE ACKNOWLEDGES HAVING READ, EXECUTED, AND RECEIVED A COPY OF THIS AGREEMENT, UNDERSTANDS HIS/HER OBLIGATIONS UNDER THIS AGREEMENT, SIGNS IT
              VOLUNTARILY, INTENDS TO BE LEGALLY BOUND BY THIS AGREEMENT, AND AGREES THAT WITH RESPECT TO THE SUBJECT MATTER HEREOF IT IS EXECUTIVE&#8217;S ENTIRE AGREEMENT WITH ANGIODYNAMICS AND SUPERSEDES ANY PREVIOUS ORAL OR WRITTEN COMMUNICATIONS,
              REPRESENTATIONS, UNDERSTANDINGS, OR AGREEMENTS WITH ANGIODYNAMICS OR ANY OF ITS OFFICIALS OR REPRESENTATIVES.</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: justify; margin-top: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Executive further acknowledges that the restrictions imposed by this Agreement are necessary and reasonable to protect AngioDynamics&#8217; business
    interests and will not preclude Executive from becoming gainfully employed in a suitable capacity following the termination of Executive&#8217;s employment with AngioDynamics given Executive&#8217;s general knowledge and experience.</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageFooter">
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 28 of 29 pages</font></div>
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div id="DSPFPageHeader">
      <div><br>
      </div>
    </div>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; margin-bottom: 36pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">IN WITNESS WHEREOF, Executive and AngioDynamics have hereunto affixed their signatures, this _____________ day of ______________________ 20
    ______.</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">___________________________________________</div>
  <div style="text-align: left; margin-bottom: 24pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Executive</div>
  <div style="text-align: left; margin-bottom: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">AngioDynamics, Inc.</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">___________________________________________</div>
  <div style="text-align: left; margin-bottom: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Signature</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">___________________________________________</div>
  <div style="text-align: left; margin-bottom: 12pt; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Print Name</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">___________________________________________</div>
  <div style="text-align: left; font-family: Arial, Helvetica, sans-serif; font-size: 12pt;">Title</div>
  <div><br>
  </div>
  <div style="margin-top: 12pt;"><br>
  </div>
  <div id="DSPFPageFooter">
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
  <div style="text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 29 of 29 pages</font>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ango-20210129.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://angiodynamics.com/20210129" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ango="http://angiodynamics.com/20210129" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ango-20210129_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ango-20210129_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://angiodynamics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ango-20210129_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ango-20210129_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://angiodynamics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ango-20210129.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://angiodynamics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>an55676910-8ki_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ango-20210129.xsd" xlink:type="simple"/>
    <context id="c20210129to20210129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2021-01-29</startDate>
            <endDate>2021-01-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20210129to20210129"
      id="Fact_f1993659f03446b9824f6becb18ab322">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="c20210129to20210129"
      id="Fact_97518236ccab4d9fa0e209b1136004fe">ANGIODYNAMICS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="c20210129to20210129"
      id="Fact_81b3ccde0c85439f82c68f05122d5984">0001275187</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20210129to20210129"
      id="Fact_aceab718735d4536a70478a0269fb809">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20210129to20210129"
      id="Fact_67fbcba2a2e14e0380d8e7866beddf7a">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20210129to20210129"
      id="Fact_d9a38016eba34534a50f765d57e4943d">2021-01-29</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20210129to20210129"
      id="Fact_81c5a0b30204438cbef5b85c602137a8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20210129to20210129"
      id="Fact_810972cd8bb647629e130bcd27e0d52a">000-50761</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20210129to20210129"
      id="Fact_b78ce3a87e714f3ba16df54db50863eb">11-3146460</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20210129to20210129"
      id="Fact_da007b33228547bf9e0df5fb71342eb1">14 Plaza Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20210129to20210129"
      id="Fact_18ceccb51a9a409285a34b7bef2bdc75">Latham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20210129to20210129"
      id="Fact_c703f87cbb1546ce895188d19f666e4b">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20210129to20210129"
      id="Fact_034b6e1581014313b3a885661f44f489">12110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20210129to20210129"
      id="Fact_127d7f6961f948f8a42e129735aeb280">518</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20210129to20210129"
      id="Fact_7cda78c5542f49dfb5f57e910303dc21">795-1400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20210129to20210129"
      id="Fact_8796b1a446cb4b82bc29c1a595a7e8b9">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20210129to20210129"
      id="Fact_6fae92d1bd494b40b6245636a07e994e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20210129to20210129"
      id="Fact_b9a187168c4d4e24937087fecda267c1">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20210129to20210129"
      id="Fact_5ff8881df085486980ed873fd5544bf7">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20210129to20210129"
      id="Fact_b2d3454ba1d6464c9762a2007005ad8b">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20210129to20210129"
      id="Fact_c70aa5f9015e4df0ac2a92ee77dc98e0">ANGO</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20210129to20210129"
      id="Fact_d656e1640dc54c609056266c40b5038b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140533465020120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 29,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANGIODYNAMICS INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3146460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">14 Plaza Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Latham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">12110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">795-1400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001275187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANGO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !S@T-2'#AEZC\!   \ @
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M>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ <X-#4B0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !S@T-2 @[,5>X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !S
M@T-2F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( '.#0U)7M+9N,P0  #\0   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !S
M@T-2@ZFE ]0!   R!@  #0              @ %V#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( '.#0U*7BKL<P    !,"   +              "  74.
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( '.#0U(<.&7J/P$  #P"   /
M          "  5X/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !S@T-2
M)!Z;HJT   #X 0  &@              @ '*$   >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " !S@T-299!YDAD!  #/ P  $P
M        @ &O$0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(  #Y$@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="an55676910-8ki.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://angiodynamics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="an55676910-8ki.htm">an55676910-8ki.htm</File>
    <File>an55676910-ex10_1.htm</File>
    <File>an55676910-ex10_2.htm</File>
    <File>ango-20210129.xsd</File>
    <File>ango-20210129_lab.xml</File>
    <File>ango-20210129_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "an55676910-8ki.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "an55676910-8ki.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ango-20210129_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ango-20210129_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ango-20210129.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ango",
   "nsuri": "http://angiodynamics.com/20210129",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "an55676910-8ki.htm",
      "contextRef": "c20210129to20210129",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://angiodynamics.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "an55676910-8ki.htm",
      "contextRef": "c20210129to20210129",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://angiodynamics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000914121-21-000581-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914121-21-000581-xbrl.zip
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M0GV4I>5'*'"F%)2 F&!5'N\=P82$."EO$SK:DCV]I:S\5P1,-AW;CS33LIS
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MF>6MMN?^[=?$R0<B31#;3  0R33C50GZ/51YM&$6\H6XD]E4"TS-T"S+]%C
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M>C3F7]$*Y84#O7&2-7 IIMHA(;]O1TB)D;*'PI<K+MSS,JN:FQT"B3RT*)&
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M2*,UV7166!I8&N&DLU#ZFR/4!;V<$EH6VIJLFUO; 6<SB_TN_S15 '17"TI
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MD8J?8<L(LW8TQZ%?0KU*KE1.7%7:A^X$\B72SNDT_LY>SCPP#]7O<8J'!.P
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M//,8N4RFIXVBP_#__?7AQ=$_ULGE?[""X8.=-N&B>K#&C@M*0^B.92='4QR
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M89IVK]6LK@)C<E0@:-2.ES>S%[ZO4>8U1UR2X[$;R*J.AY!@ WF'FK$MPD+
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M]VLH&E72X]U$[1<3(E#/1=J6.E!MME=D4^O9A YD6VFD"C5A1IJ.QN^3\?;
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M<=W;=:9P.9N!I3;VZI@B1L_6 :36Q.@K*K#K\4NQ,'N;(HZ*#OLV<M:&DBK
MNI^)8>+$E++HFBUGB1OSI#O+[XIJ\GR)^/5OX_V_=7W)B1D)7!#7@J)-GT-\
M)0C(^)(:JLQ5.4,9$9O"!5+6W2@=M5_3'D</,XF^9%5CTE2@ E=D)G]74.-D
M57?K/@O=Q('T.+#%15'DAJR%SI;KJRKPR-<;RQ(W717-18^=@[*.L76;NX"_
M:;^T"6<:JNI0H*O8Z!&!2I6+>UN(C2L+3%,Z*U$/*] 9HC2C'N"=B1<30O5F
MJ\"X(>STN3NXFW%G<GJ(L!H#J36"-F:>UIM%&0A0!N@&Q'Z[58/2)'9=E_UX
M.HG1T1UD D-286N<>F&_EL2]-L28(;2Q*-&]:0+NW?INQ:V1;7_&6[5;W0J
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M5=>9T4,D>[%Z ?=-TKKLY$.-:=\^,C%@%-\4Z:^ZVO?437):7IK'@5NIB<!
M5:<U!?>=@-]:ZH:U!%CLPD!1B'AW$5('C?).8W(+-5K987V^7^NP])1'SL2T
M0.@R0+/E]76NFMUAG26,!67_ L00$^#"S([?#BRU*+F-D4D%+Q98.8. ,CW-
M"QG6JF0T Y&D"8R%0ZXJO^$L1B:;G>64,\;P<!?7W7@J:"_*@A;)HMGG>DU$
M^GL!B:A'AZOIA^VNIDT"'/!>\XA1FV'?.] ;5)IQ'9\#!U1(4S1A#B!&5EVB
M'EV!KE6F9"/P9BUZD\*'MG!%+"9!3S;7,H"M:Y+H+)LQ48YL0IYXK9T'<P7#
M6!0@C3$\!SMK*-3EA*7U-,"V*;*&*TJ:S%;J'\Z!5#$\S^%SP2%HZ+&@1M88
M(3$HK*R!Z,$66F^FV J%"W3G==;\6:/LY#V [32?--@<OD=MU2?39#Q.!Z#1
MR)RA\.M4210)U$.58[R<$O;+/B=$SWIQJK)9[XVO=(R^TN\WOM(Q^DI73T]T
MN.AN\+<FF;G>2=J)RN3R6 9CP:>Q\$]G=(,V7%*C-V3%?S3 DY-TU1*;+RE8
M'O;545'R//+'IE(,,53&G-[F* L*%0C.1M<9!ST5,.0*65"QI ?7KTN;G&PJ
M:OT[U(C (@DBS!/E7:'W%/4&^J^N#8UF\.Y9I,M4VY*N*!T8NB4)ZUT/73O9
M:1 _94OMSG9#4UH]B3+32J_"C()<?A%CRO^YLLA$"#HIWY)++>.6)3+/7)P@
M[=< FW+>X3^>NWDZ]34M[[%?_$H3NQ7?*.6J1P?:2))RG+)MD]?CY+/E;@%[
M6R.3*O.^F@4<%4+9[&]COY8>C]_:P):T17=[L]*^DAW0;5"9 FI3@3WK"B;M
M8K7QZ039VT"AVD6FK3H+F\B)[&"> ZOI4_5U>IXLZ*CXUN,UF->OL8T3N]$[
MN4+M9D:=1"'>! ;RD5SS+<53,'BHO!GM%-TQZFLE4O3B5QQJ]-(UM&>:3@GH
MO0\ JY]48KF[@%9G"'&U?S#9.:#BMR9C5M]"!#ZP26_6_3^F#;SU<HUT7KT-
M%I&=J=RF_3".6)JV43%'1=E7ZZ/LTMXDK3TLV?:W$W/<U'R]1FJ2=D ALM/K
M''&V/IVDS!8>)CL/':CST1[^HS42%3U>@Y1$VGEN3B;I:W*F%IV>9*,BVD_K
M(]JK".R<'J*1G\>I[^[!+%FIX9U#?,875A34F#99J\7*5"IE^NK>_#(CMRBH
M!WJS(7VQ4\X<2?:,_EV5;C<D"]F#]BL?G5K2"(::$DEME9N4K_5&/1FNS,7[
MNB7MKL8?+:(8W7*",;"XO*DPVX8RG@DG/@":<=E/V7V+C?<.M%D:;*N$JUQ*
M/H_C.W8* W2-#+KP:_(0SW'=ICJVZ2R-%X-.JV4Q =='K2.2\F0OURC%<X")
M49R3(@5<GIG,QWF"/O\K5?7XNLF[C09 [RY2@XC^M$]"I]0<G^S1'3>RMN5-
MB(X.%.<TI],@K27&BA86K(UD-LRYO63D85ZS1]]JT@Y^F#\A#>W57A.]Q8@D
M+UA;X52>632SP$.MV(R<1DRD:6*=@D#+-Z?<%H)88;0;V I,O#1'MTY![62-
M,;OQS([1,_MLXYG]MCVS1MJ6!-2.7"Q-TJ@D[@1'5-7P.;OQ:G1[V98YX:VD
M@I4YEHDF?C+;ZLH1CV=1D2GA^+L#?D&E[JGF9CU!S"*_2@W<'()H1,%49043
M#>$NHB N4TJ7N"JR*Y;'49-06=\ED+"JN: >9HF>J*9< &D2U7& "+?/(NG&
MNFV!@W4<.C&N%'1X8DD+]\00F5'KK_*!R:"SMY,S(GJ?\&JMHTE2< (3X/Q8
MZ7@D+;[IZ\XJH"3T/:$X!9T%YOBX2:1.EP6/96Y2.M2:(#9OE5#IA$'"V*_7
MUK,'@< HJ-TGL"290#R<CJ[IZJNT:&4M*7P3]NOIG<YN;]/C6=?0<I<#M\FS
M8)7*&Z68D]KS3-AM+$J0Z"P46;U4YJ1A?X 9+TCGO$V+LO/"72?2+1/ NWV8
MI>%NTG:*HE$52C0?N+D26CHIDU['&;U_C2/I,9@=?1!_E +N9C()6UAUE'JK
M63(,MTL?E17VQG0W6H<=UJY!7VK(.GD=CB%F>3"I_15IOKI)\WA<K0/]3#5U
M<4+OJ<87M5 ZJ5P83V*BY3@))1N*Y)\QDO$_\H?&N<AN"&2W D:"I]FD6/@6
MK2DI1B):)7V:3FNR&*C*<^OQWE],^ 6&-J'4JZN";EH4UQ:!N U90=D:L/=-
M_,0.)^2\$]/:6RB 30_T_#DBT2%!+_!A 'I[7D7\E>98%*!EX15(! DC;K,R
M6@@C8RE+KOD7*Z%-?^7FV'K/^+L?UQR4GR;**E$GVDA_'C^.Y"'SZ ].CI'5
MRTF-IM99VDFDO?(EZ1"%XU!Z[KT5ELWTXIXH&'GN2"S;'=%TPH'!: G'+>EU
M^_(M%M?NSFB##+L2S.>>VZ$[32\QD)Z4JVLS-=^/8;]FW%?2:"(Q=AVT$L1/
MX\+&M.H'X-0UO12A)'3KG/KIRE4$R%FY:)&4#8NSIH1TC?Q,%$)>6V0H9D4\
MEPJK#EC$DZ&K'^NN6>LP;LN40 X6H)/H*+BYU4^&1-/&B#7C]&A?W#[GU*$.
M*PC@$),B1+BR5US"CE7@<VGNBV!OR#E8.:ZQ"3.VWKPN=E#!3F#]#[Y[:'B-
MG1(Q$H:.0/!57@+D%1(9)^^6O;QO)SJM*P.SS@Y10C/+\%8R7!,&H[I"CT!&
M4-X#$_XFF(K+54K:V;C[FKD ;@I&DJ0>6I2D=MV'L)QS;:_=V.P+.FK:<X1J
MGJ[ALT<0^?/PJ_HQ]*E$@,501\[9/=J5D:Y$ZNWC+ITK^\<B+EP^AGV/-T(U
MV)+M2>B#:&/27G3>7M!OA/=O'&O8FXM$%PQD<'9<AD*J#V((&>J#?&-L)RY:
M"9E)H<B.W(Q0Q%P#45I=I@O-I>L2=J%2MK?D%'A[3.NH:X.<87#D!1VN+;!S
M:29[R]8([>&G#%^>O%$XGJRJ< PN>Z"MC3:A-DZ[,3KM]O<V7KO[]]J9&\8
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MB2'=R8H?%37_MDYJT@E=P5O< Q3&\'("W9;FII+4EM YT8 WVQHR7Z,)DUN
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M="!]H]+%ANGS6ND43;3EA&D)9K=V0#/Z>"=Y\-9WZL!R+UU& 9N]S&GJII.
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MZOFT6[K"A$]4G&%N*BFM..3VM*+* K!P 3!C>0CI*:1?NJ-F,)/B]HW0Z7.
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M3RC599%1G&7J_J(+8ORO<YU12%]C5JO@R2.<;J=81R>D5Y*97Y3F21+.40:
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M1?@/_O7RS_\!4$L! A0#%     @ <X-#4GRCT#S(&   980  !(
M     ( !     &%N-34V-S8Y,3 M.&MI+FAT;5!+ 0(4 Q0    ( '.#0U):
M >W?8ED  $4A @ 5              "  ?@8  !A;C4U-C<V.3$P+65X,3!?
M,2YH=&U02P$"% ,4    " !S@T-2<;<-2116  #Y& ( %0
M@ &-<@  86XU-38W-CDQ,"UE>#$P7S(N:'1M4$L! A0#%     @ <X-#4OR?
M]"1S P  DQ   !$              ( !U,@  &%N9V\M,C R,3 Q,CDN>'-D
M4$L! A0#%     @ <X-#4KNB;?^>"   (%D  !4              ( !=LP
M &%N9V\M,C R,3 Q,CE?;&%B+GAM;%!+ 0(4 Q0    ( '.#0U*J@"PP[P4
M *<_   5              "  4?5  !A;F=O+3(P,C$P,3(Y7W!R92YX;6Q0
52P4&      8 !@"+ 0  :=L

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
